fbpx
Wikipedia

Management of HIV/AIDS

December 27, 2022

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection.[1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death.[2] HAART also prevents the transmission of HIV between serodiscordant same sex and opposite sex partners so long as the HIV-positive partner maintains an undetectable viral load.[3]

Treatment has been so successful that in many parts of the world, HIV has become a chronic condition in which progression to AIDS is increasingly rare. Anthony Fauci, head of the United States National Institute of Allergy and Infectious Diseases, has written, "With collective and resolute action now and a steadfast commitment for years to come, an AIDS-free generation is indeed within reach." In the same paper, he noted that an estimated 700,000 lives were saved in 2010 alone by antiretroviral therapy.[4] As another commentary in The Lancet noted, "Rather than dealing with acute and potentially life-threatening complications, clinicians are now confronted with managing a chronic disease that in the absence of a cure will persist for many decades."[5]

The United States Department of Health and Human Services and the World Health Organization[6] (WHO) recommend offering antiretroviral treatment to all patients with HIV.[7] Because of the complexity of selecting and following a regimen, the potential for side effects, and the importance of taking medications regularly to prevent viral resistance, such organizations emphasize the importance of involving patients in therapy choices and recommend analyzing the risks and the potential benefits.[7]

The WHO has defined health as more than the absence of disease. For this reason, many researchers have dedicated their work to better understanding the effects of HIV-related stigma, the barriers it creates for treatment interventions, and the ways in which those barriers can be circumvented.[8][9]

Classes of medication

 
Schematic description of the mechanism of the four classes of available antiretroviral drugs against HIV

There are six classes of drugs, which are usually used in combination, to treat HIV infection. Antiretroviral (ARV) drugs are broadly classified by the phase of the retrovirus life-cycle that the drug inhibits. Typical combinations include two nucleoside reverse-transcriptase inhibitors (NRTI) as a "backbone" along with one non-nucleoside reverse-transcriptase inhibitor (NNRTI), protease inhibitor (PI) or integrase inhibitors (also known as integrase nuclear strand transfer inhibitors or INSTIs) as a "base."[7]

Entry inhibitors

Entry inhibitors (or fusion inhibitors) interfere with binding, fusion and entry of HIV-1 to the host cell by blocking one of several targets. Maraviroc and enfuvirtide are the two available agents in this class. Maraviroc works by targeting CCR5, a co-receptor located on human helper T-cells. Caution should be used when administering this drug, however, due to a possible shift in tropism which allows HIV to target an alternative co-receptor such as CXCR4.[citation needed]

In rare cases, individuals may have a mutation in the CCR5 delta gene which results in a nonfunctional CCR5 co-receptor and in turn, a means of resistance or slow progression of the disease. However, as mentioned previously, this can be overcome if an HIV variant that targets CXCR4 becomes dominant.[10] To prevent fusion of the virus with the host membrane, enfuvirtide can be used. Enfuvirtide is a peptide drug that must be injected and acts by interacting with the N-terminal heptad repeat of gp41 of HIV to form an inactive hetero six-helix bundle, therefore preventing infection of host cells.[11]

Nucleoside/nucleotide reverse-transcriptase inhibitors

Nucleoside reverse-transcriptase inhibitors (NRTI) and nucleotide reverse-transcriptase inhibitors (NtRTI) are nucleoside and nucleotide analogues which inhibit reverse transcription. HIV is an RNA virus, so it can not be integrated into the DNA in the nucleus of the human cell unless it is first "reverse" transcribed into DNA. Since the conversion of RNA to DNA is not naturally done in the mammalian cell, it is performed by a viral protein, reverse transcriptase, which makes it a selective target for inhibition. NRTIs are chain terminators. Once NRTIs are incorporated into the DNA chain, their lack of a 3' OH group prevents the subsequent incorporation of other nucleosides. Both NRTIs and NtRTIs act as competitive substrate inhibitors. Examples of NRTIs include zidovudine, abacavir, lamivudine, emtricitabine, and of NtRTIs – tenofovir and adefovir.[12]

Non-nucleoside reverse-transcriptase inhibitors

Non-nucleoside reverse-transcriptase inhibitors (NNRTI) inhibit reverse transcriptase by binding to an allosteric site of the enzyme; NNRTIs act as non-competitive inhibitors of reverse transcriptase. NNRTIs affect the handling of substrate (nucleotides) by reverse transcriptase by binding near the active site. NNRTIs can be further classified into 1st generation and 2nd generation NNRTIs. 1st generation NNRTIs include nevirapine and efavirenz. 2nd generation NNRTIs are etravirine and rilpivirine.[12] HIV-2 is naturally resistant to NNRTIs.[13]

Integrase inhibitors

Integrase inhibitors (also known as integrase nuclear strand transfer inhibitors or INSTIs) inhibit the viral enzyme integrase, which is responsible for integration of viral DNA into the DNA of the infected cell. There are several integrase inhibitors under clinical trial,[when?] and raltegravir became the first to receive FDA approval in October 2007. Raltegravir has two metal binding groups that compete for substrate with two Mg2+ ions at the metal binding site of integrase. As of early 2022, four other clinically approved integrase inhibitors are elvitegravir, dolutegravir, bictegravir, and cabotegravir.[14]

Protease inhibitors

Protease inhibitors block the viral protease enzyme necessary to produce mature virions upon budding from the host membrane. Particularly, these drugs prevent the cleavage of gag and gag/pol precursor proteins.[15] Virus particles produced in the presence of protease inhibitors are defective and mostly non-infectious. Examples of HIV protease inhibitors are lopinavir, indinavir, nelfinavir, amprenavir and ritonavir. Darunavir and atazanavir are recommended as first line therapy choices.[7] Maturation inhibitors have a similar effect by binding to gag, but development of two experimental drugs in this class, bevirimat and vivecon, was halted in 2010.[16] Resistance to some protease inhibitors is high. Second generation drugs have been developed that are effective against otherwise resistant HIV variants.[15]

Combination therapy

The life cycle of HIV can be as short as about 1.5 days from viral entry into a cell, through replication, assembly, and release of additional viruses, to infection of other cells.[17] HIV lacks proofreading enzymes to correct errors made when it converts its RNA into DNA via reverse transcription. Its short life-cycle and high error rate cause the virus to mutate very rapidly, resulting in a high genetic variability. Most of the mutations either are inferior to the parent virus (often lacking the ability to reproduce at all) or convey no advantage, but some of them have a natural selection superiority to their parent and can enable them to slip past defenses such as the human immune system and antiretroviral drugs. The more active copies of the virus, the greater the possibility that one resistant to antiretroviral drugs will be made.[18]

When antiretroviral drugs are used improperly, multi-drug resistant strains can become the dominant genotypes very rapidly. In the era before multiple drug classes were available (pre-1997), the reverse-transcriptase inhibitors zidovudine, didanosine, zalcitabine, stavudine, and lamivudine were used serially or in combination leading to the development of multi-drug resistant mutations.[19]

In contrast, antiretroviral combination therapy defends against resistance by creating multiple obstacles to HIV replication. This keeps the number of viral copies low and reduces the possibility of a superior mutation.[18] If a mutation that conveys resistance to one of the drugs arises, the other drugs continue to suppress reproduction of that mutation. With rare exceptions, no individual antiretroviral drug has been demonstrated to suppress an HIV infection for long; these agents must be taken in combinations in order to have a lasting effect. As a result, the standard of care is to use combinations of antiretroviral drugs.[7] Combinations usually consist of three drugs from at least two different classes.[7] This three drug combination is commonly known as a triple cocktail.[20] Combinations of antiretrovirals are subject to positive and negative synergies, which limits the number of useful combinations.[citation needed]

Because of HIV's tendency to mutate, when patients who have started an antiretrovial regimen fail to take it regularly, resistance can develop.[21] On the other hand, patients who take their medications regularly can stay on one regimen without developing resistance.[21] This greatly increases life expectancy and leaves more drugs available to the individual should the need arise.[citation needed]

 
A 2016 advertisement from NIAID promoting the advancement of single-pill antiretroviral drug combinations

In recent years,[when?] drug companies have worked together to combine these complex regimens into single-pill fixed-dose combinations.[22] More than 20 antiretroviral fixed-dose combinations have been developed. This greatly increases the ease with which they can be taken, which in turn increases the consistency with which medication is taken (adherence),[23] and thus their effectiveness over the long-term.

Adjunct treatment

Although antiretroviral therapy has helped to improve the quality of life of people living with HIV, there is still a need to explore other ways to further address the disease burden. One such potential strategy that was investigated was to add interleukin 2 as an adjunct to antiretroviral therapy for adults with HIV. A Cochrane review included 25 randomized controlled trials that were conducted across six countries.[24] The researchers found that interleukin 2 increases the CD4 immune cells, but does not make a difference in terms of death and incidence of other infections. Furthermore, there is probably an increase in side-effects with interleukin 2. The findings of this review do not support the use of interleukin 2 as an add-on treatment to antiretroviral therapy for adults with HIV.[citation needed]

Treatment guidelines

Initiation of antiretroviral therapy

Antiretroviral drug treatment guidelines have changed over time. Before 1987, no antiretroviral drugs were available and treatment consisted of treating complications from opportunistic infections and malignancies. After antiretroviral medications were introduced, most clinicians agreed that HIV positive patients with low CD4 counts should be treated, but no consensus formed as to whether to treat patients with high CD4 counts.[25]

In April 1995, Merck and the National Institute of Allergy and Infectious Diseases began recruiting patients for a trial examining the effects of a three drug combination of the protease inhibitor indinavir and two nucleoside analogs.[26] illustrating the substantial benefit of combining 2 NRTIs with a new class of antiretrovirals, protease inhibitors, namely indinavir. Later that year David Ho became an advocate of this "hit hard, hit early" approach with aggressive treatment with multiple antiretrovirals early in the course of the infection.[27] Later reviews in the late 90s and early 2000s noted that this approach of "hit hard, hit early" ran significant risks of increasing side effects and development of multidrug resistance, and this approach was largely abandoned. The only consensus was on treating patients with advanced immunosuppression (CD4 counts less than 350/μL).[28] Treatment with antiretrovirals was expensive at the time, ranging from $10,000 to $15,000 a year.[29]

The timing of when to start therapy has continued to be a core controversy within the medical community, though recent[when?] studies have led to more clarity. The NA-ACCORD[30] study observed patients who started antiretroviral therapy either at a CD4 count of less than 500 versus less than 350 and showed that patients who started ART at lower CD4 counts had a 69% increase in the risk of death.[30] In 2015 the START[31] and TEMPRANO[32] studies both showed that patients lived longer if they started antiretrovirals at the time of their diagnosis, rather than waiting for their CD4 counts to drop to a specified level.

Other arguments for starting therapy earlier are that people who start therapy later have been shown to have less recovery of their immune systems,[33] and higher CD4 counts are associated with less cancer.[34]

The European Medicines Agency (EMA) has recommended the granting of marketing authorizations for two new antiretroviral (ARV) medicines, rilpivirine (Rekambys) and cabotegravir (Vocabria), to be used together for the treatment of people with human immunodeficiency virus type 1 (HIV-1) infection.[35] The two medicines are the first ARVs that come in a long-acting injectable formulation.[35] This means that instead of daily pills, people receive intramuscular injections monthly or every two months.[35]

The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors (INIs).[35]

Treatment as prevention

A separate argument for starting antiretroviral therapy that has gained more prominence is its effect on HIV transmission. ART reduces the amount of virus in the blood and genital secretions.[36][37] This has been shown to lead to dramatically reduced transmission of HIV when one partner with a suppressed viral load (<50 copies/ml) has sex with a partner who is HIV negative. In clinical trial HPTN 052, 1763 serodiscordant heterosexual couples in 9 countries were planned to be followed for at least 10 years, with both groups receiving education on preventing HIV transmission and condoms, but only one group getting ART. The study was stopped early (after 1.7 years) for ethical reasons when it became clear that antiviral treatment provided significant protection. Of the 28 couples where cross-infection had occurred, all but one had taken place in the control group consistent with a 96% reduction in risk of transmission while on ART. The single transmission in the experimental group occurred early after starting ART before viral load was likely to be suppressed.[38] Pre-exposure prophylaxis (PrEP) provides HIV-negative individuals with medication—in conjunction with safer-sex education and regular HIV/STI screenings—in order to reduce the risk of acquiring HIV.[39] In 2011, the journal Science gave the Breakthrough of the Year award to treatment as prevention.[40]

In July 2016 a consensus document was created by the Prevention Access Campaign which has been endorsed by over 400 organisations in 58 countries. The consensus document states that the risk of HIV transmission from a person living with HIV who has been undetectable for a minimum of six months is negligible to non-existent, with negligible being defined as "so small or unimportant to be not worth considering". The Chair of the British HIV Association (BHIVA), Chloe Orkin, stated in July 2017 that 'there should be no doubt about the clear and simple message that a person with sustained, undetectable levels of HIV virus in their blood cannot transmit HIV to their sexual partners.'[41]

Furthermore, the PARTNER study,[42] which ran from 2010 to 2014, enrolled 1166 serodiscordant couples (where one partner is HIV positive and the other is negative) in a study that found that the estimated rate of transmission through any condomless sex with the HIV-positive partner taking ART with an HIV load less than 200 copies/ml was zero.[42]

In summary, as the WHO HIV treatment guidelines state, "The ARV regimens now available, even in the poorest countries, are safer, simpler, more effective and more affordable than ever before."[43]

There is a consensus among experts that, once initiated, antiretroviral therapy should never be stopped. This is because the selection pressure of incomplete suppression of viral replication in the presence of drug therapy causes the more drug sensitive strains to be selectively inhibited. This allows the drug resistant strains to become dominant. This in turn makes it harder to treat the infected individual as well as anyone else they infect.[7] One trial showed higher rates of opportunistic infections, cancers, heart attacks and death in patients who periodically interrupted their ART.[44][45]

Guideline sources

There are several treatment guidelines for HIV-1 infected adults in the developed world (that is, those countries with access to all or most therapies and laboratory tests). In the United States there are both the International AIDS Society-USA (IAS-USA) (a 501(c)(3) not-for-profit organization in the US)[46] as well as the US government's Department of Health and Human Services guidelines.[7] In Europe there are the European AIDS Clinical Society guidelines.[47]

For resource limited countries, most national guidelines closely follow the World Health Organization (WHO) guidelines.[6]

Guidelines

The guidelines use new criteria to consider starting HAART, as described below. However, there remain a range of views on this subject and the decision of whether to commence treatment ultimately rests with the patient and his or her doctor.[citation needed]

The US DHHS guidelines (published April 8, 2015) state:[citation needed]

  • Antiretroviral therapy (ART) is recommended for all HIV-infected individuals to reduce the risk of disease progression.
  • ART also is recommended for HIV-infected individuals for the prevention of transmission of HIV.
  • Patients starting ART should be willing and able to commit to treatment and understand the benefits and risks of therapy and the importance of adherence. Patients may choose to postpone therapy, and providers, on a case-by-case basis, may elect to defer therapy on the basis of clinical and/or psychosocial factors.

The newest WHO guidelines (dated September 30, 2015) now agree and state:[6]

  • Antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count

Baseline resistance

Baseline resistance is the presence of resistance mutations in patients who have never been treated before for HIV. In countries with a high rate of baseline resistance, resistance testing is recommended before starting treatment; or, if the initiation of treatment is urgent, then a "best guess" treatment regimen should be started, which is then modified on the basis of resistance testing.[13] In the UK, there is 11.8% medium to high-level resistance at baseline to the combination of efavirenz + zidovudine + lamivudine, and 6.4% medium to high level resistance to stavudine + lamivudine + nevirapine.[48] In the US, 10.8% of one cohort of patients who had never been on ART before had at least one resistance mutation in 2005.[49] Various surveys in different parts of the world have shown increasing or stable rates of baseline resistance as the era of effective HIV therapy continues.[50][51][52][53] With baseline resistance testing, a combination of antiretrovirals that are likely to be effective can be customized for each patient.[citation needed]

Regimens

Most HAART regimens consist of three drugs: 2 NRTIs ("backbone")+ a PI/NNRTI/INSTI ("base"). Initial regimens use "first-line" drugs with a high efficacy and low side-effect profile.

The US DHHS preferred initial regimens for adults and adolescents in the United States, as of April 2015, are:[7]

Both efavirenz and nevirapine showed similar benefits when combined with NRTI respectively.[54]

In the case of the protease inhibitor based regimens, ritonavir is used at low doses to inhibit cytochrome p450 enzymes and "boost" the levels of other protease inhibitors, rather than for its direct antiviral effect. This boosting effect allows them to be taken less frequently throughout the day.[55] Cobicistat is used with elvitegravir for a similar effect but does not have any direct antiviral effect itself.[56]

The WHO preferred initial regimen for adults and adolescents as of June 30, 2013 is:[43]

  • tenofovir + lamivudine (or emtricitabine) + efavirenz

Special populations

Acute infection

In the first six months after infection HIV viral loads tend to be elevated and people are more often symptomatic than in later latent phases of HIV disease. There may be special benefits to starting antiretroviral therapy early during this acute phase, including lowering the viral "set-point" or baseline viral load, reduce the mutation rate of the virus, and reduce the size of the viral reservoir (See section below on viral reservoirs).[7] The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed the time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped.[57]

Since viral loads are usually very high during acute infection, this period carries an estimated 26 times higher risk of transmission.[58] By treating acutely infected patients, it is presumed that it could have a significant impact on decreasing overall HIV transmission rates since lower viral loads are associated with lower risk of transmission (See section on treatment as prevention). However an overall benefit has not been proven and has to be balanced with the risks of HIV treatment. Therapy during acute infection carries a grade BII recommendation from the US DHHS.[7]

Children

HIV can be especially harmful to infants and children, with one study in Africa showing that 52% of untreated children born with HIV had died by age 2.[59] By five years old, the risk of disease and death from HIV starts to approach that of young adults. The WHO recommends treating all children less than 5 years old, and starting all children older than 5 with stage 3 or 4 disease or CD4 <500 cells/ml.[43] DHHS guidelines are more complicated but recommend starting all children less than 12 months old and children of any age who have symptoms.[60]

As for which antiretrovirals to use, this is complicated by the fact that many children who are born to mothers with HIV are given a single dose of nevirapine (an NNRTI) at the time of birth to prevent transmission. If this fails it can lead to NNRTI resistance.[61] Also, a large study in Africa and India found that a PI based regimen was superior to an NNRTI based regimen in children less than 3 years who had never been exposed to NNRTIs in the past.[62] Thus the WHO recommends PI based regimens for children less than 3.

The WHO recommends for children less than 3 years:[43]

  • abacavir (or zidovudine) + lamivudine + lopinivir + ritonivir

and for children 3 years to less than 10 years and adolescents <35 kilograms:

US DHHS guidelines are similar but include PI based options for children > 3 years old.[60]

A systematic review assessed the effects and safety of abacavir-containing regimens as first-line therapy for children between 1 month and 18 years of age when compared to regimens with other NRTIs.[63] This review included two trials and two observational studies with almost eleven thousand HIV infected children and adolescents. They measured virologic suppression, death and adverse events. The authors found that there is no meaningful difference between abacavir-containing regimens and other NRTI-containing regimens. The evidence is of low to moderate quality and therefore it is likely that future research may change these findings.[citation needed]

Pregnant women

Main articles: HIV and pregnancy and Breastfeeding by HIV infected mothers

The goals of treatment for pregnant women include the same benefits to the mother as in other infected adults as well as prevention of transmission to her child. The risk of transmission from mother to child is proportional to the plasma viral load of the mother. Untreated mothers with a viral load >100,000 copies/ml have a transmission risk of over 50%.[64] The risk when viral loads are < 1000 copies/ml are less than 1%.[65] ART for mothers both before and during delivery and to mothers and infants after delivery are recommended to substantially reduce the risk of transmission.[66] The mode of delivery is also important, with a planned Caesarian section having a lower risk than vaginal delivery or emergency Caesarian section.[65]

HIV can also be detected in breast milk of infected mothers and transmitted through breast feeding.[67] The WHO balances the low risk of transmission through breast feeding from women who are on ART with the benefits of breastfeeding against diarrhea, pneumonia and malnutrition. It also strongly recommends that breastfeeding infants receive prophylactic ART.[43] In the US, the DHHS recommends against women with HIV breastfeeding.[66]

Older adults

With improvements in HIV therapy, several studies now estimate that patients on treatment in high-income countries can expect a normal life expectancy.[68][69] This means that a higher proportion of people living with HIV are now older and research is ongoing into the unique aspects of HIV infection in the older adult. There is data that older people with HIV have a blunted CD4 response to therapy but are more likely to achieve undetectable viral levels.[70] However, not all studies have seen a difference in response to therapy.[71] The guidelines do not have separate treatment recommendations for older adults, but it is important to take into account that older patients are more likely to be on multiple non-HIV medications and consider drug interactions with any potential HIV medications.[72] There are also increased rates of HIV associated non-AIDS conditions (HANA) such as heart disease, liver disease and dementia that are multifactorial complications from HIV, associated behaviors, coinfections like hepatitis B, hepatitis C, and human papilloma virus (HPV) as well as HIV treatment.[72]

Adults with depression

Many factors may contribute to depression in adults living with HIV, such as the effects of the virus on the brain, other infections or tumours, antiretroviral drugs and other medical treatment.[73] Rates of major depression are higher in people living with HIV compared to the general population, and this may negatively influence antiretroviral treatment. In a systematic review, Cochrane researchers assessed whether giving antidepressants to adults living with both HIV and depression may improve depression.[73] Ten trials, of which eight were done in high-income countries, with 709 participants were included. Results indicated that antidepressants may be better in improving depression compared to placebo, but the quality of the evidence is low and future research is likely to impact on the findings.[citation needed]

Concerns

There are several concerns about antiretroviral regimens that should be addressed before initiating:

  • Intolerance: The drugs can have serious side-effects which can lead to harm as well as keep patients from taking their medications regularly.
  • Resistance: Not taking medication consistently can lead to low blood levels that foster drug resistance.[74]
  • Cost: The WHO maintains a database of world ART costs[75] which have dropped dramatically in recent[when?] years as more first line drugs have gone off-patent.[76] A one pill, once a day combination therapy has been introduced in South Africa for as little as $10 per patient per month.[77] One 2013 study estimated an overall cost savings to ART therapy in South Africa given reduced transmission.[78] In the United States, new on-patent regimens can cost up to $28,500 per patient, per year.[79][80]
  • Public health: Individuals who fail to use antiretrovirals as directed can develop multi-drug resistant strains which can be passed onto others.[81]

Response to therapy

Virologic response

Suppressing the viral load to undetectable levels (<50 copies per ml) is the primary goal of ART.[55] This should happen by 24 weeks after starting combination therapy.[82] Viral load monitoring is the most important predictor of response to treatment with ART.[83] Lack of viral load suppression on ART is termed virologic failure. Levels higher than 200 copies per ml is considered virologic failure, and should prompt further testing for potential viral resistance.[7]

Research has shown that people with an undetectable viral load are unable to transmit the virus through condomless sex with a partner of either gender. The 'Swiss Statement' of 2008 described the chance of transmission as 'very low' or 'negligible,'[84] but multiple studies have since shown that this mode of sexual transmission is impossible where the HIV-positive person has a consistently undetectable viral load. This discovery has led to the formation of the Prevention Access Campaign are their 'U=U' or 'Undetectable=Untransmittable' public information strategy,[85][86] an approach that has gained widespread support amongst HIV/AIDS-related medical, charitable, and research organisations.[41] The studies demonstrating that U=U is an effective strategy for preventing HIV transmission in serodiscordant couples so long as "the partner living with HIV [has] a durably suppressed viral load" include:[87] Opposites Attract,[88] PARTNER 1,[42] PARTNER 2,[89][90] (for male-male couples)[87] and HPTN052[91] (for heterosexual couples).[87] In these studies, couples where one partner was HIV-positive and one partner was HIV-negative were enrolled and regular HIV testing completed. In total from the four studies, 4097 couples were enrolled over four continents and 151,880 acts of condomless sex were reported, there were zero phylogenetically linked transmissions of HIV where the positive partner had an undetectable viral load.[92] Following this the U=U consensus statement advocating the use of 'zero risk' was signed by hundreds of individuals and organisations including the US CDC, British HIV Association and The Lancet medical journal.[41] The importance of the final results of the PARTNER 2 study were described by the medical director of the Terrence Higgins Trust as "impossible to overstate," while lead author Alison Rodger declared that the message that "undetectable viral load makes HIV untransmittable ... can help end the HIV pandemic by preventing HIV transmission."[93] The authors summarised their findings in The Lancet as follows:[89]

Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV.[89]

This result is consistent with the conclusion presented by Anthony S. Fauci, the Director of the National Institute of Allergy and Infectious Diseases for the U.S. National Institutes of Health, and his team in a viewpoint published in the Journal of the American Medical Association, that U=U is an effective HIV prevention method when an undetectable viral load is maintained.[3][87]

Immunologic response

CD4 cell counts are another key measure of immune status and ART effectiveness.[82] CD4 counts should rise 50 to 100 cells per ml in the first year of therapy.[55] There can be substantial fluctuation in CD4 counts of up to 25% based on the time of day or concomitant infections.[94] In one long-term study, the majority of increase in CD4 cell counts was in the first two years after starting ART with little increase afterwards. This study also found that patients who began ART at lower CD4 counts continued to have lower CD4 counts than those who started at higher CD4 counts.[95] When viral suppression on ART is achieved but without a corresponding increase in CD4 counts it can be termed immunologic nonresponse or immunologic failure. While this is predictive of worse outcomes, there is no consensus on how to adjust therapy to immunologic failure and whether switching therapy is beneficial. DHHS guidelines do not recommend switching an otherwise suppressive regimen.[7][96]

Innate lymphoid cells (ILC) are another class of immune cell that is depleted during HIV infection. However, if ART is initiated before this depletion at around 7 days post infection, ILC levels can be maintained. While CD4 cell counts typically replenish after effective ART, ILCs depletion is irreversible with ART initiated after the depletion despite suppression of viremia.[97] Since one of the roles of ILCs is to regulate the immune response to commensal bacteria and to maintain an effective gut barrier,[98] it has been hypothesized that the irreversible depletion of ILCs plays a role in the weakened gut barrier of HIV patients, even after successful ART.[99]

Salvage therapy

In patients who have persistently detectable viral loads while taking ART, tests can be done to investigate whether there is drug resistance. Most commonly a genotype is sequenced which can be compared with databases of other HIV viral genotypes and resistance profiles to predict response to therapy.[100] Resistance testing may improve virological outcomes in those who have treatment failures. However, there is lack of evidence of effectiveness of such testing in those who have not done any treatment before.[101]

If there is extensive resistance a phenotypic test of a patient's virus against a range of drug concentrations can be performed, but is expensive and can take several weeks, so genotypes are generally preferred.[7] Using information from a genotype or phenotype, a regimen of 3 drugs from at least 2 classes is constructed that will have the highest probability of suppressing the virus. If a regimen cannot be constructed from recommended first line agents it is termed salvage therapy, and when 6 or more drugs are needed it is termed mega-HAART.[102]

Structured treatment interruptions

Drug holidays (or "structured treatment interruptions") are intentional discontinuations of antiretroviral drug treatment. As mentioned above, randomized controlled studies of structured treatment interruptions have shown higher rates of opportunistic infections, cancers, heart attacks and death in patients who took drug holidays.[44][45][103] With the exception of post-exposure prophylaxis (PEP), treatment guidelines do not call for the interruption of drug therapy once it has been initiated.[7][43][82][103]

Adverse effects

Each class and individual antiretroviral carries unique risks of adverse side effects.

NRTIs

The NRTIs can interfere with mitochondrial DNA synthesis and lead to high levels of lactate and lactic acidosis, liver steatosis, peripheral neuropathy, myopathy and lipoatrophy.[55] First-line NRTIs such as lamivudine/emtrictabine, tenofovir, and abacavir are less likely to cause mitochondrial dysfunction.[104][105]

Mitochondrial Haplogroups(mtDNA), non pathologic mutations inherited from the maternal line, have been linked to the efficacy of CD4+ count following ART.[106][107][108][109] Idiosyncratic toxicity with mtDNA haplogroup is also well studied.(Boeisteril et al., 2007).[110]

NNRTIs

NNRTIs are generally safe and well tolerated. The main reason for discontinuation of efavirenz is neuro-psychiatric effects including suicidal ideation. Nevirapine can cause severe hepatotoxicity, especially in women with high CD4 counts.[111]

Protease inhibitors

Protease inhibitors (PIs) are often given with ritonavir, a strong inhibitor of cytochrome P450 enzymes, leading to numerous drug-drug interactions. They are also associated with lipodystrophy, elevated triglycerides and elevated risk of heart attack.[112]

Integrase inhibitors

Integrase inhibitors (INSTIs) are among the best tolerated of the antiretrovirals with excellent short and medium term outcomes. Given their relatively new development there is less long term safety data. They are associated with an increase in creatinine kinase levels and rarely myopathy.[113]

Post-exposure prophylaxis (PEP)

Further information: Post-exposure prophylaxis § HIV

When people are exposed to HIV-positive infectious bodily fluids either through skin puncture, contact with mucous membranes or contact with damaged skin, they are at risk for acquiring HIV. Pooled estimates give a risk of transmission with puncture exposures of 0.3%[114] and mucous membrane exposures 0.63%.[115] United States guidelines state that "feces, nasal secretions, saliva, sputum, sweat, tears, urine, and vomitus are not considered potentially infectious unless they are visibly bloody."[116] Given the rare nature of these events, rigorous study of the protective abilities of antiretrovirals are limited but do suggest that taking antiretrovirals afterwards can prevent transmission.[117] It is unknown if three medications are better than two. The sooner after exposure that ART is started the better, but after what period they become ineffective is unknown, with the US Public Health Service Guidelines recommending starting prophylaxis up to a week after exposure.[116] They also recommend treating for a duration of four weeks based on animal studies. Their recommended regimen is emtricitabine + tenofovir + raltegravir (an INSTI). The rationale for this regimen is that it is "tolerable, potent, and conveniently administered, and it has been associated with minimal drug interactions."[116] People who are exposed to HIV should have follow up HIV testing at six, 12, and 24 weeks.[citation needed]

Pregnancy planning

Further information: HIV and pregnancy

Women with HIV have been shown to have decreased fertility which can affect available reproductive options.[118] In cases where the woman is HIV negative and the man is HIV positive, the primary assisted reproductive method used to prevent HIV transmission is sperm washing followed by intrauterine insemination (IUI) or in vitro fertilization (IVF). Preferably this is done after the man has achieved an undetectable plasma viral load.[119] In the past there have been cases of HIV transmission to an HIV-negative partner through processed artificial insemination,[120] but a large modern series in which followed 741 couples where the man had a stable viral load and semen samples were tested for HIV-1, there were no cases of HIV transmission.[121]

For cases where the woman is HIV positive and the man is HIV negative, the usual method is artificial insemination.[119] With appropriate treatment the risk of mother-to-child infection can be reduced to below 1%.[122]

History

Several buyers clubs sprang up since 1986 to combat HIV. The drug zidovudine (AZT), a nucleoside reverse-transcriptase inhibitor (NRTI), was not effective on its own. It was approved by the US FDA in 1987.[123] The FDA bypassed stages of its review for safety and effectiveness in order to distribute this drug earlier.[124] Subsequently, several more NRTIs were developed but even in combination were unable to suppress the virus for long periods of time and patients still inevitably died.[125] To distinguish from this early antiretroviral therapy (ART), the term highly active antiretroviral therapy (HAART) was introduced. In 1996 two sequential publications in The New England Journal of Medicine by Hammer and colleagues[126] and Gulick and colleagues[26] illustrated the substantial benefit of combining 2 NRTIs with a new class of antiretrovirals, protease inhibitors, namely indinavir. This concept of 3-drug therapy was quickly incorporated into clinical practice and rapidly showed impressive benefit with a 60% to 80% decline in rates of AIDS, death, and hospitalization.[2]

As HAART became widespread, fixed dose combinations were made available to ease the administration. Later, the term combination antiretroviral therapy (cART) gained favor with some physicians as a more accurate name, not conveying to patients any misguided idea of the nature of the therapy.[127] Today multidrug, highly effective regimens are long since the default in ART, which is why they are increasingly called simply ART instead of HAART or cART.[127] This retronymic process is linguistically comparable to the way that the words electronic computer and digital computer at first were needed to make useful distinctions in computing technology, but with the later irrelevance of the distinction, computer alone now covers their meaning. Thus as "all computers are digital now", so "all ART is combination ART now." However, the names HAART and cART, reinforced by thousands of earlier mentions in medical literature still being regularly cited, also remain in use.[citation needed]

Research

People living with HIV can expect to live a nearly normal life span if able to achieve durable viral suppression on combination antiretroviral therapy. However this requires lifelong medication and will still have higher rates of cardiovascular, kidney, liver and neurologic disease.[128] This has prompted further research towards a cure for HIV.

Patients cured of HIV infection

The so-called "Berlin patient" has been potentially cured of HIV infection and has been off of treatment since 2006 with no detectable virus.[129] This was achieved through two bone marrow transplants that replaced his immune system with a donor's that did not have the CCR5 cell surface receptor, which is needed for some variants of HIV to enter a cell.[130] Bone marrow transplants carry their own significant risks including potential death and was only attempted because it was necessary to treat a blood cancer he had. Attempts to replicate this have not been successful and given the risks, expense and rarity of CCR5 negative donors, bone marrow transplant is not seen as a mainstream option.[128] It has inspired research into other methods to try to block CCR5 expression through gene therapy. A procedure zinc-finger nuclease-based gene knockout has been used in a Phase I trial of 12 humans and led to an increase in CD4 count and decrease in their viral load while off antiretroviral treatment.[131] Attempt to reproduce this failed in 2016. Analysis of the failure showed that gene therapy only successfully treats 11-28% of cells, leaving the majority of CD4+ cells capable of being infected. The analysis found that only patients where less than 40% of cells were infected had reduced viral load. The Gene therapy was not effective if the native CD4+ cells remained. This is the main limitation which must be overcome for this treatment to become effective.[132]

After the "Berlin patient", two additional patients with both HIV infection and cancer were reported to have no traceable HIV virus after successful stem cell transplants. Virologist Annemarie Wensing of the University Medical Center Utrecht announced this development during her presentation at the 2016 "Towards an HIV Cure" symposium.[133][134][135] However, these two patients are still on antiretroviral therapy, which is not the case for the Berlin patient. Therefore, it is not known whether or not the two patients are cured of HIV infection. The cure might be confirmed if the therapy were to be stopped and no viral rebound occurred.[136]

In March 2019, a second patient, referred to as the "London Patient", was confirmed to be in complete remission of HIV. Like the Berlin Patient, the London Patient received a bone marrow transplant from a donor who has the same CCR5 mutation. He has been off antiviral drugs since September 2017, indicating the Berlin Patient was not a "one-off".[137][138]

Alternative approaches aiming to mimic one’s biological immunity to HIV through the absence or mutation of the CCR5 gene is being conducted in current research efforts. The efforts of which are done through the introduction of induced pluripotent stem cells that have been CCR5 disrupted through the CRISPR/Cas9 gene editing system.[139][140]

Viral reservoirs

The main obstacle to complete elimination of HIV infection by conventional antiretroviral therapy is that HIV is able to integrate itself into the DNA of host cells and rest in a latent state, while antiretrovirals only attack actively replicating HIV. The cells in which HIV lies dormant are called the viral reservoir, and one of the main sources is thought to be central memory and transitional memory CD4+ T cells.[141] In 2014 there were reports of the cure of HIV in two infants,[142] presumably due to the fact that treatment was initiated within hours of infection, preventing HIV from establishing a deep reservoir.[143] There is work being done[when?] to try to activate reservoir cells into replication so that the virus is forced out of latency and can be attacked by antiretrovirals and the host immune system. Targets include histone deacetylase (HDAC) which represses transcription and if inhibited can lead to increased cell activation. The HDAC inhibitors valproic acid and vorinostat have been used in human trials with only preliminary results so far.[144][145]

Immune activation

Even with all latent virus deactivated, it is thought that a vigorous immune response will need to be induced to clear all the remaining infected cells.[128] Strategies include using cytokines to restore CD4+ cell counts as well as therapeutic vaccines to prime immune responses.[146] One such candidate vaccine is Tat Oyi, developed by Biosantech.[147] This vaccine is based on the HIV protein tat. Animal models have shown the generation of neutralizing antibodies and lower levels of HIV viremia.[148]

Sequential mRNA Vaccine

HIV vaccine development is an active area of research and an important tool for managing the global AIDS epidemic. Research into a vaccine for HIV has been ongoing for decades with no lasting success for preventing infection.[149] The rapid development, though, of mRNA vaccines to deal with the COVID-19 pandemic may provide a new path forward.[citation needed]

Like SARS-CoV-2, the virus that causes COVID-19, HIV has a spike protein. In retroviruses like HIV, the spike protein is formed by two proteins expressed by the Env gene. This viral envelope binds to the host cell’s receptor and is what gains the virus entry into the cell.[150] With mRNA vaccines, mRNA or messenger RNA, contains the instructions for how to make the spike protein. The mRNA is put into lipid-based nanoparticles for drug delivery. This was a key breakthrough in optimizing the efficiency and efficacy of in vivo delivery.[151][152] When the vaccine is injected, the mRNA enters cells and joins up with a ribosome. The ribosome then translates the mRNA instructions into the spike protein. The immune system detects the presence of the spike protein and B cells, a type of white blood cell, begin to develop antibodies. Should the actual virus later enter the system, the external spike protein will be recognized by memory B cells, whose function is to memorize the characteristics of the original antigen. Memory B cells then produce the antibodies, hopefully destroying the virus before it can bind to another cell and repeat the HIV life cycle.[153] 

SARS-CoV-2 and HIV-1 have similarities—notably both are RNA viruses—but there are important differences. As a retrovirus, HIV-1 can insert a copy of its RNA genome into the host’s DNA, making total eradication more difficult.[154] The virus is also highly mutable making it a challenge for the adaptive immune system to develop a response. As a chronic infection, HIV-1 and the adaptive immune system undergo reciprocal selective pressures leading to the evolutionary arms race of coevolution.[155]

Broadly neutralizing HIV-1 antibodies, or bnAbs, have been shown to attach to the Env spike protein envelope regardless of the specific HIV mutations.[156][157][158] This bodes well for vaccine development. Complicating matters, though, naive B cells—mature B cells not yet exposed to any antigen and are the progenitors of bnAbs—are rare. Further, the mutation events needed to turn these B cells into bnAbs are also rare.[159][160] Because of this, there is a growing consensus that an effective HIV vaccine will need to create not only humoral (antibody-mediated) immunity, but a T-cell-mediated immunity.[161][159]

mRNA vaccines have advantages over traditional vaccines which may help deal with some of the challenges presented by the HIV virus. The mRNA in the vaccine only codes for the protein spike, not the whole virus, so the possibility of reverse transcription, where the virus copies its genetic material into the host’s genome, is not present. Another advantage when compared to traditional vaccines is the speed of development. mRNA vaccines take months not years, which means a multipart sequential vaccine regime is possible.[citation needed]

Attempts to elicit an immune response that triggers broadly neutralizing antibodies (bnAbs) with a single vaccine dose have been unsuccessful. A multipart sequential mRNA vaccine regime, however, might guide the immune response in the right direction. The first shot triggers an immune response for the correct naive B cells. Later vaccinations encourage the development of these cells further, eventually turning them into memory b cells, and later into plasma cells, which can secrete the broadly neutralizing antibodies:

In essence, the sequential immunization approach represents an attempt to mimic Env evolution that would occur with natural infection…. In contrast to traditional prime/boost strategies, in which the same immunogen is used repeatedly for vaccination, the sequential immunization approach relies on a series of different immunogens with the goal of eventually inducing bnAb(s).[159]

A Phase 1 clinical trial by Scripps Research and the International AIDS Vaccine Initiative of an mRNA vaccine showed that 97 percent of participants had the desired initial “priming” immune response of naive b cells.[160] This is a positive result for developing the first shot in a vaccine sequence. Moderna is partnering with Scripps and the International AIDS Vaccine Initiative for a follow-up phase 1 clinical trial of an HIV mRNA vaccine (mRNA-1644) starting later in 2021.[162]

Drug advertisements

Direct-to-consumer and other advertisements for HIV drugs in the past were criticized for their use of healthy, glamorous models rather than typical people with HIV/AIDS. Usually, these people will present with debilitating conditions or illnesses as a result of HIV/AIDS. In contrast, by featuring people in unrealistically strenuous activities, such as mountain climbing;[163] this proved to be offensive and insensitive to the suffering of people who are HIV positive. The US FDA reprimanded multiple pharmaceutical manufacturers for publishing such adverts in 2001, as the misleading advertisements harmed consumers by implying unproven benefits and failing to disclose important information about the drugs.[164] Overall, some drug companies chose not to present their drugs in a realistic way, which consequently harmed the general public's ideas[citation needed], suggesting that HIV would not affect you as much as suggested. This led to people not wanting to get tested[citation needed], for fear of being HIV positive, because at the time (in the 80s and 90s particularly), having contracted HIV was seen as a death sentence, as there was no known cure. An example of such a case is Freddie Mercury[citation needed], who died in 1991, aged 45, of AIDS-related pneumonia.

Beyond medical management

The preamble to the World Health Organization's Constitution defines health as "a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity."[165] Those living with HIV today are met with other challenges that go beyond the singular goal of lowering their viral load. A 2009 meta-analysis studying the correlates of HIV-stigma found that individuals living with higher stigma burden were more likely to have poorer physical and mental health.[9] Insufficient social support and delayed diagnosis due to decreased frequency of HIV testing and knowledge of risk reduction were cited as some of the reasons.[9][166][8][167][168] People living with HIV (PLHIV) have lower health related quality of life (HRQoL) scores than do the general population.[167][166] The stigma of having HIV is often compounded with the stigma of identifying with the LGBTQ community or the stigma of being an injecting drug user (IDU) even though heterosexual sexual transmission accounts for 85% of all HIV-1 infections worldwide.[169][103] AIDS has been cited as the most heavily stigmatized medical condition among infectious diseases.[168] Part of the consequence of this stigma toward PLHIV is the belief that they are seen as responsible for their status and less deserving of treatment.[169][9]

A 2016 study sharing the WHO's definition of health critiques its 90-90-90 target goal, which is part of a larger strategy that aims to eliminate the AIDS epidemic as a public health threat by 2030, by arguing that it does not go far enough in ensuring the holistic health of PLHIV.[8] The study suggests that maintenance of HIV and AIDS should go beyond the suppression of viral load and the prevention of opportunistic infection. It proposes adding a 'fourth 90' addressing a new 'quality of life' target that would focus specifically on increasing the quality of life for those that are able to suppress their viral load to undetectable levels along with new metrics to track the progress toward that target.[8] This study serves as an example of the shifting paradigm in the dynamics of the health care system from being heavily 'disease-oriented' to more 'human-centered'. Though questions remain of what exactly a more 'human-centered' method of treatment looks like in practice, it generally aims to ask what kind of support, other than medical support, PLHIV need to cope with and eliminate HIV-related stigmas.[9][8] Campaigns and marketing aimed at educating the general public in order to reduce any misplaced fears of HIV contraction is one example.[9] Also encouraged is the capacity-building and guided development of PLHIV into more leadership roles with the goal of having a greater representation of this population in decision making positions.[9] Structural legal intervention has also been proposed, specifically referring to legal interventions to put in place protections against discrimination and improve access to employment opportunities.[9] On the side of the practitioner, greater competence for the experience of people living with HIV is encouraged alongside the promotion of an environment of nonjudgment and confidentiality.[9]

Psychosocial group interventions such as psychotherapy, relaxation, group support, and education may have some beneficial effects on depression in HIV positive people.[170]

Food insecurity

The successful treatment and management of HIV/AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications, preventing opportunistic infection, and food access etc. Food insecurity is a condition in which households lack access to adequate food because of limited money or other resources. Food insecurity is a global issue that have affect billions of people yearly including those living in developed countries.[citation needed]

Food insecurity is a major public health disparity in the United States of America, which significantly affects minority groups, people living at or below the poverty line, and those who are living with one or more morbidity. As of December 31, 2017, there were approximately 126,742 people living with HIV/AIDS (PLWHA) in NYC, of whom 87.6% can be described as living with some level of poverty and food insecurity as reported by the NYC Department of Health March 31, 2019.[171] Having access to a consistent food supply that is safe and healthy is an important part in the treatment and management of HIV/AIDS. PLWHA are also greatly affected by food inequities and food deserts which causes them to be food insecure. Food insecurity, which can cause malnutrition, can also negatively impact HIV treatment and recovery from opportunistic infections. Similarly, PLWHA require additional calories and nutritionally support that require foods free from contamination to prevent further immunocompromising. Food insecurity can further exacerbate the progression of HIV/AIDS and can prevent PLWHA from consistently following their prescribed regimen, which will lead to poor outcomes.[citation needed]

It is imperative that these food insecurity among PLWHA are addressed and rectified to reduce this health inequity.[172][circular reference] It is important to recognized that socioeconomic status, access to medical care, geographic location, public policy, race and ethnicity all play a pivotal role in the treatment and management of HIV/AIDS. The lack of sufficient and constant income does limit the options for food, treatment, and medications. The same can be inferred for those who are among the oppressed groups in society who are marginalized and may be less inclined or encouraged to seek care and assistance. Endeavors to address food insecurity should be included in HIV treatment programs and may help improve health outcomes if it also focuses on health equity among the diagnosed as much as it focuses on medications. Access to consistently safe and nutritious foods is one of the most important facets in ensuring PLWHA are being provided the best possible care. By altering the narratives for HIV treatment so that more support can be garnered to reduce food insecurity and other health disparities mortality rates will decrease for people living with HIV/AIDS.[citation needed]

See also

References

  1. ^ Arachchige AS (2021). "A universal CAR-NK cell approach for HIV eradication". AIMS Allergy and Immunology. 5 (3): 192–194. doi:10.3934/Allergy.2021015.
  2. ^ a b Moore RD, Chaisson RE (October 1999). "Natural history of HIV infection in the era of combination antiretroviral therapy". AIDS. 13 (14): 1933–42. doi:10.1097/00002030-199910010-00017. PMID 10513653.
  3. ^ a b Eisinger RW, Dieffenbach CW, Fauci AS (February 2019). "HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable". JAMA. 321 (5): 451–452. doi:10.1001/jama.2018.21167. PMID 30629090. S2CID 58599661.
  4. ^ Fauci AS, Folkers GK (July 2012). "Toward an AIDS-free generation". JAMA. 308 (4): 343–4. doi:10.1001/jama.2012.8142. PMID 22820783.
  5. ^ Deeks SG, Lewin SR, Havlir DV (November 2013). "The end of AIDS: HIV infection as a chronic disease". Lancet. 382 (9903): 1525–33. doi:10.1016/S0140-6736(13)61809-7. PMC 4058441. PMID 24152939.
  6. ^ a b c . World Health Organization. Archived from the original on March 26, 2005. Retrieved 2015-10-27.
  7. ^ a b c d e f g h i j k l m n o "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents" (PDF). US Department of Health and Human Services. 2015-04-08. {{cite journal}}: Cite journal requires |journal= (help)
  8. ^ a b c d e Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo Valero J, et al. (June 2016). "Beyond viral suppression of HIV - the new quality of life frontier". BMC Medicine. 14 (1): 94. doi:10.1186/s12916-016-0640-4. PMC 4916540. PMID 27334606.
  9. ^ a b c d e f g h i Logie C, Gadalla TM (June 2009). "Meta-analysis of health and demographic correlates of stigma towards people living with HIV". AIDS Care. 21 (6): 742–53. doi:10.1080/09540120802511877. PMID 19806490. S2CID 29881807.
  10. ^ Lieberman-Blum SS, Fung HB, Bandres JC (July 2008). "Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection". Clinical Therapeutics. 30 (7): 1228–50. doi:10.1016/S0149-2918(08)80048-3. PMID 18691983.
  11. ^ Bai Y, Xue H, Wang K, Cai L, Qiu J, Bi S, et al. (February 2013). "Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket". Amino Acids. 44 (2): 701–13. doi:10.1007/s00726-012-1394-8. PMID 22961335. S2CID 18521851.
  12. ^ a b Das K, Arnold E (April 2013). "HIV-1 reverse transcriptase and antiviral drug resistance. Part 1". Current Opinion in Virology. 3 (2): 111–8. doi:10.1016/j.coviro.2013.03.012. PMC 4097814. PMID 23602471.
  13. ^ a b Geretti, ed. (2006). "9". Antiretroviral Resistance in Clinical Practice. Mediscript. ISBN 978-0-955-16690-7.
  14. ^ Métifiot M, Marchand C, Pommier Y (2013). "HIV integrase inhibitors: 20-year landmark and challenges". Antiviral Agents. Advances in Pharmacology. Vol. 67. pp. 75–105. doi:10.1016/B978-0-12-405880-4.00003-2. ISBN 9780124058804. PMC 7569752. PMID 23885999.
  15. ^ a b Wensing AM, van Maarseveen NM, Nijhuis M (January 2010). "Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance". Antiviral Research. 85 (1): 59–74. doi:10.1016/j.antiviral.2009.10.003. PMID 19853627.
  16. ^ . AIDSmeds. 8 June 2012. Archived from the original on 8 September 2015. Retrieved 27 June 2012.
  17. ^ Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (March 1996). "HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time". Science. 271 (5255): 1582–6. Bibcode:1996Sci...271.1582P. CiteSeerX 10.1.1.34.7762. doi:10.1126/science.271.5255.1582. PMID 8599114. S2CID 13638059.
  18. ^ a b Smyth RP, Davenport MP, Mak J (November 2012). "The origin of genetic diversity in HIV-1". Virus Research. 169 (2): 415–29. doi:10.1016/j.virusres.2012.06.015. PMID 22728444.
  19. ^ Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, et al. (November 1996). "Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain". The Journal of Infectious Diseases. 174 (5): 962–8. doi:10.1093/infdis/174.5.962. PMID 8896496.
  20. ^ Henkel J (July–August 1999). . FDA Consumer. Food and Drug Administration, US Dept. of Health and Human Services. Archived from the original on 2009-01-14.
  21. ^ a b Bangsberg DR, Kroetz DL, Deeks SG (May 2007). "Adherence-resistance relationships to combination HIV antiretroviral therapy". Current HIV/AIDS Reports. 4 (2): 65–72. doi:10.1007/s11904-007-0010-0. PMID 17547827. S2CID 45429207.
  22. ^ "Fixed-dose combinations". AIDSmap. March 2011. Retrieved 2014-04-09.
  23. ^ Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (August 2007). "Fixed-dose combinations improve medication compliance: a meta-analysis". The American Journal of Medicine. 120 (8): 713–9. doi:10.1016/j.amjmed.2006.08.033. PMID 17679131.
  24. ^ Onwumeh J, Okwundu CI, Kredo T (May 2017). "Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults". The Cochrane Database of Systematic Reviews. 2017 (5): CD009818. doi:10.1002/14651858.CD009818.pub2. PMC 5458151. PMID 28542796.
  25. ^ Darbyshire J (1995). "Perspectives in drug therapy of HIV infection". Drugs. 49 Suppl 1 (Supplement 1): 1–3, discussion 38–40. doi:10.2165/00003495-199500491-00003. PMID 7614897. S2CID 754662.
  26. ^ a b Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA (September 1997). "Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy". The New England Journal of Medicine. 337 (11): 734–9. doi:10.1056/NEJM199709113371102. PMID 9287228.
  27. ^ Ho DD (August 1995). "Time to hit HIV, early and hard". The New England Journal of Medicine. 333 (7): 450–1. doi:10.1056/NEJM199508173330710. PMID 7616996.
  28. ^ Harrington M, Carpenter CC (June 2000). "Hit HIV-1 hard, but only when necessary". Lancet. 355 (9221): 2147–52. doi:10.1016/S0140-6736(00)02388-6. PMID 10902643. S2CID 22747572.
  29. ^ Sonenklar C (2011). "Chapter 6: Treatment for HIV and AIDS". AIDS. USA Today Health Reports: Diseases and Disorders. Minneapolis, MN: Twenty-First Century Books. pp. 90–101. ISBN 9780822585817.
  30. ^ a b Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. (April 2009). "Effect of early versus deferred antiretroviral therapy for HIV on survival". The New England Journal of Medicine. 360 (18): 1815–26. doi:10.1056/NEJMoa0807252. PMC 2854555. PMID 19339714.
  31. ^ Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. (August 2015). "Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection". The New England Journal of Medicine. 373 (9): 795–807. doi:10.1056/NEJMoa1506816. PMC 4569751. PMID 26192873.
  32. ^ Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. (August 2015). "A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa". The New England Journal of Medicine. 373 (9): 808–22. doi:10.1056/NEJMoa1507198. hdl:10044/1/41218. PMID 26193126.
  33. ^ Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. (March 2009). "Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment". Clinical Infectious Diseases. 48 (6): 787–94. doi:10.1086/597093. PMC 2720023. PMID 19193107.
  34. ^ Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. (October 2008). "HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies". AIDS. 22 (16): 2143–53. doi:10.1097/QAD.0b013e3283112b77. PMC 2715844. PMID 18832878.
  35. ^ a b c d "First long-acting injectable antiretroviral therapy for HIV recommended approval". European Medicines Agency (EMA) (Press release). 16 October 2020. Retrieved 16 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  36. ^ Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, et al. (February 2007). "Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding". AIDS. 21 (4): 501–7. doi:10.1097/QAD.0b013e32801424bd. PMID 17301569. S2CID 21335467.
  37. ^ Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. (January 2000). "Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study". AIDS. 14 (2): 117–21. CiteSeerX 10.1.1.567.3563. doi:10.1097/00002030-200001280-00006. PMID 10708281. S2CID 3035239.
  38. ^ Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. (August 2011). "Prevention of HIV-1 infection with early antiretroviral therapy". The New England Journal of Medicine. 365 (6): 493–505. doi:10.1056/NEJMoa1105243. PMC 3200068. PMID 21767103.
  39. ^ Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD (November 2013). "Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?". Lancet. 382 (9903): 1515–24. doi:10.1016/S0140-6736(13)61998-4. PMC 3880570. PMID 24152938.
  40. ^ Cohen J (December 2011). "Breakthrough of the year. HIV treatment as prevention". Science. 334 (6063): 1628. Bibcode:2011Sci...334.1628C. doi:10.1126/science.334.6063.1628. PMID 22194547.
  41. ^ a b c "Consensus statement: Risk of Sexual Transmission of HIV from a Person Living with HIV who has an Undetectable Viral Load". Prevention Access Campaign. 21 July 2016. Retrieved 2 April 2019. Note: When the statement and list of endorsements was retrieved, it had last been updated on 23 August 2018 and included "over 850 organizations from nearly 100 countries."
  42. ^ a b c Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. (July 2016). "Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy". JAMA. 316 (2): 171–81. doi:10.1001/jama.2016.5148. PMID 27404185. PARTNER (Partners of People on ART—A New Evaluation of the Risks)
  43. ^ a b c d e f Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection<. WHO. June 30, 2013. p. 38. ISBN 978-92-4-150572-7.
  44. ^ a b El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C (November 2006). "CD4+ count-guided interruption of antiretroviral treatment" (PDF). The New England Journal of Medicine. 355 (22): 2283–96. doi:10.1056/NEJMoa062360. PMID 17135583. S2CID 32501272.
  45. ^ a b Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. (September 2007). "Risk of cancers during interrupted antiretroviral therapy in the SMART study". AIDS. 21 (14): 1957–63. doi:10.1097/QAD.0b013e3282ed6338. PMID 17721103. S2CID 16090838.
  46. ^ Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. (2014-07-23). "Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel". JAMA. 312 (4): 410–25. doi:10.1001/jama.2014.8722. PMID 25038359.
  47. ^ "EACS Guidelines 8.0". www.eacsociety.org. Retrieved 2016-01-14.
  48. ^ Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. (December 2005). "Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study". BMJ. 331 (7529): 1368. doi:10.1136/bmj.38665.534595.55. PMC 1309643. PMID 16299012.
  49. ^ Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al. (February 2005). "Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy". Clinical Infectious Diseases. 40 (3): 468–74. doi:10.1086/427212. PMID 15668873.
  50. ^ Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, et al. (November 2013). "National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011". The Journal of Antimicrobial Chemotherapy. 68 (11): 2626–31. doi:10.1093/jac/dkt238. PMID 23798669.
  51. ^ Sungkanuparph S, Pasomsub E, Chantratita W (Jan–Feb 2014). "Surveillance of transmitted HIV drug resistance in antiretroviral-naive patients aged less than 25 years, in Bangkok, Thailand". Journal of the International Association of Providers of AIDS Care. 13 (1): 12–4. doi:10.1177/2325957413488200. PMID 23708678.
  52. ^ Gagliardo C, Brozovich A, Birnbaum J, Radix A, Foca M, Nelson J, et al. (March 2014). "A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City". Clinical Infectious Diseases. 58 (6): 865–72. doi:10.1093/cid/ciu003. PMC 3988426. PMID 24429431.
  53. ^ Pérez L, Kourí V, Alemán Y, Abrahantes Y, Correa C, Aragonés C, et al. (June 2013). "Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba". Infection, Genetics and Evolution. 16: 144–50. doi:10.1016/j.meegid.2013.02.002. PMID 23416260.
  54. ^ Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N, et al. (Cochrane Infectious Diseases Group) (December 2016). "Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals". The Cochrane Database of Systematic Reviews. 2016 (12): CD004246. doi:10.1002/14651858.CD004246.pub4. PMC 5450880. PMID 27943261.
  55. ^ a b c d "Antiretroviral Therapy for Human Immunodeficiency Virus Infection". Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (7th ed.). Churchill Livingstone. 2009. ISBN 978-0-443-06839-3.
  56. ^ Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS (October 2012). "Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro". Antimicrobial Agents and Chemotherapy. 56 (10): 5409–13. doi:10.1128/AAC.01089-12. PMC 3457391. PMID 22850510.
  57. ^ Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, et al. (January 2013). "Short-course antiretroviral therapy in primary HIV infection". The New England Journal of Medicine. 368 (3): 207–17. doi:10.1056/NEJMoa1110039. PMC 4131004. PMID 23323897.
  58. ^ Hollingsworth TD, Anderson RM, Fraser C (September 2008). "HIV-1 transmission, by stage of infection". The Journal of Infectious Diseases. 198 (5): 687–93. doi:10.1086/590501. PMID 18662132.
  59. ^ Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F (October 8, 2004). "Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis". Lancet. 364 (9441): 1236–43. doi:10.1016/S0140-6736(04)17140-7. PMID 15464184. S2CID 24511465.
  60. ^ a b "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" (PDF). US Department of Health and Human Services. February 12, 2014. pp. 50–61. Retrieved April 11, 2014.
  61. ^ Musiime V, Ssali F, Kayiwa J, Namala W, Kizito H, Kityo C, Mugyenyi P (October 2009). "Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine". AIDS Research and Human Retroviruses. 25 (10): 989–96. doi:10.1089/aid.2009.0054. PMID 19778270.
  62. ^ Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. (June 2012). "Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children". The New England Journal of Medicine. 366 (25): 2380–9. doi:10.1056/NEJMoa1113249. PMC 3443859. PMID 22716976.
  63. ^ Adetokunboh OO, Schoonees A, Balogun TA, Wiysonge CS (October 2015). "Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis". BMC Infectious Diseases. 15 (1): 469. doi:10.1186/s12879-015-1183-6. PMC 4623925. PMID 26502899.
  64. ^ Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF (August 1999). "Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group". The New England Journal of Medicine. 341 (6): 394–402. doi:10.1056/NEJM199908053410602. PMID 10432324.
  65. ^ a b European Collaborative Study (February 2005). "Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy". Clinical Infectious Diseases. 40 (3): 458–65. doi:10.1086/427287. PMID 15668871.
  66. ^ a b "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States" (PDF). US DHHS. March 28, 2014. Retrieved 2014-04-11.
  67. ^ Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, Mbori-Ngacha DA, et al. (March 2003). "Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease". The Journal of Infectious Diseases. 187 (5): 741–7. doi:10.1086/374273. PMC 3384731. PMID 12599047.
  68. ^ May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. (May 2014). "Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy". AIDS. 28 (8): 1193–202. doi:10.1097/QAD.0000000000000243. PMC 4004637. PMID 24556869.
  69. ^ Nakagawa F, May M, Phillips A (February 2013). "Life expectancy living with HIV: recent estimates and future implications". Current Opinion in Infectious Diseases. 26 (1): 17–25. doi:10.1097/QCO.0b013e32835ba6b1. PMID 23221765. S2CID 7554571.
  70. ^ Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP (April 2007). "Older age and the response to and tolerability of antiretroviral therapy". Archives of Internal Medicine. 167 (7): 684–91. doi:10.1001/archinte.167.7.684. PMID 17420427.
  71. ^ Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA (October 2010). "Virologic and immunologic response to HAART, by age and regimen class". AIDS. 24 (16): 2469–79. doi:10.1097/QAD.0b013e32833e6d14. PMC 3136814. PMID 20829678.
  72. ^ a b Greene M, Justice AC, Lampiris HW, Valcour V (April 2013). "Management of human immunodeficiency virus infection in advanced age". JAMA. 309 (13): 1397–405. doi:10.1001/jama.2013.2963. PMC 3684249. PMID 23549585.
  73. ^ a b Eshun-Wilson I, Siegfried N, Akena DH, Stein DJ, Obuku EA, Joska JA (January 2018). "Antidepressants for depression in adults with HIV infection". The Cochrane Database of Systematic Reviews. 1 (1): CD008525. doi:10.1002/14651858.CD008525.pub3. PMC 6491182. PMID 29355886.
  74. ^ Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR (June 2009). "Antiretroviral medication adherence and the development of class-specific antiretroviral resistance". AIDS. 23 (9): 1035–46. doi:10.1097/QAD.0b013e32832ba8ec. PMC 2704206. PMID 19381075.
  75. ^ . World Health Organization. Archived from the original on May 20, 2006. Retrieved 2014-04-11.
  76. ^ "Antiretroviral Drug Prices". Avert. Retrieved 2014-04-12.
  77. ^ "New one-pill, $10-per-month anti-retroviral AIDS treatment debuts in South Africa". The Raw Story. Agence France-Presse. 2013.
  78. ^ Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. (October 2013). "Cost-effectiveness of HIV treatment as prevention in serodiscordant couples". The New England Journal of Medicine. 369 (18): 1715–25. doi:10.1056/NEJMsa1214720. PMC 3913536. PMID 24171517.
  79. ^ Horn T (August 28, 2012). "Activists Protest Stribild's $28,500 Price Tag". AIDSMeds. Retrieved 2014-04-11.
  80. ^ "Stribild". GoodRx. Retrieved 2014-04-11.
  81. ^ Beardsley T (July 1998). "Coping with HIV's ethical dilemmas". Scientific American. 279 (1): 106–7. Bibcode:1998SciAm.279a.106B. doi:10.1038/scientificamerican0798-106. PMID 9648307.
  82. ^ a b c Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. (July 2012). "Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel". JAMA. 308 (4): 387–402. doi:10.1001/jama.2012.7961. PMID 22820792. S2CID 205038135.
  83. ^ Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA (May 1999). "The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs". AIDS. 13 (7): 797–804. doi:10.1097/00002030-199905070-00008. PMID 10357378.
  84. ^ Swiss National AIDS Commission (15 October 2016). "The Swiss statement". HIV i-Base. Retrieved 2 April 2019.
  85. ^ The Lancet Hiv (November 2017). "U=U taking off in 2017". Editorial. The Lancet. HIV. 4 (11): e475. doi:10.1016/S2352-3018(17)30183-2. PMID 29096785.
  86. ^ "Can't Pass It On". Terrence Higgins Trust. 2019. from the original on 7 April 2019. Retrieved 2 April 2019.
  87. ^ a b c d Hoffman H (10 January 2019). "The science is clear: with HIV, undetectable equals untransmittable" (Press release). National Institutes of Health. National Institute of Allergy and Infectious Diseases. Retrieved 3 May 2019. NIAID Director Anthony S. Fauci, M.D., and colleagues summarize results from large clinical trials and cohort studies validating U=U. The landmark NIH-funded HPTN 052 clinical trial showed that no linked HIV transmissions occurred among HIV serodifferent heterosexual couples when the partner living with HIV had a durably suppressed viral load. Subsequently, the PARTNER and Opposites Attract studies confirmed these findings and extended them to male-male couples. ... The success of U=U as an HIV prevention method depends on achieving and maintaining an undetectable viral load by taking ART daily as prescribed.
  88. ^ Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. (August 2018). "Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study". The Lancet. HIV. 5 (8): e438–e447. doi:10.1016/S2352-3018(18)30132-2. PMID 30025681. S2CID 51702998.
  89. ^ a b c Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. (May 2019). "Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study". Lancet. 393 (10189): 2428–2438. doi:10.1016/S0140-6736(19)30418-0. PMC 6584382. PMID 31056293.
  90. ^ Rodger, A. (for the PARTNER study group) (July 2018). Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: The PARTNER2 Study extended results in gay men. AIDS2018: 22nd International AIDS Conference. Amsterdam, the Netherlands. Retrieved 2 April 2019.
  91. ^ Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. (September 2016). "Antiretroviral Therapy for the Prevention of HIV-1 Transmission". The New England Journal of Medicine. 375 (9): 830–9. doi:10.1056/NEJMoa1600693. PMC 5049503. PMID 27424812.
  92. ^ Hodson M (17 November 2017). U=U: Talking to patients about transmission risk (PDF). British HIV Association Autumn Conference 2017. Retrieved 3 May 2019. (abstract for presentation on behalf of NAM / AIDSmap)
  93. ^ Boseley S, Devlin H (3 May 2019). "End to AIDS in sight as huge study finds drugs stop HIV transmission". The Guardian. Retrieved 3 May 2019.
  94. ^ Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA (January 1994). "Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring". The Journal of Infectious Diseases. 169 (1): 28–36. doi:10.1093/infdis/169.1.28. PMID 7903975.
  95. ^ Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD (July 2010). "Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection". AIDS. 24 (12): 1867–76. doi:10.1097/QAD.0b013e32833adbcf. PMC 3018341. PMID 20467286.
  96. ^ Gazzola L, Tincati C, Bellistrì GM, Monforte A, Marchetti G (February 2009). "The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options". Clinical Infectious Diseases. 48 (3): 328–37. doi:10.1086/695852. PMID 19123868.
  97. ^ Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al. (February 2016). "Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression". Immunity. 44 (2): 391–405. doi:10.1016/j.immuni.2016.01.006. PMC 6836297. PMID 26850658.
  98. ^ Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA, Kunisawa J, et al. (June 2012). "Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria". Science. 336 (6086): 1321–5. Bibcode:2012Sci...336.1321S. doi:10.1126/science.1222551. PMC 3659421. PMID 22674331.
  99. ^ Chung CY, Alden SL, Funderburg NT, Fu P, Levine AD (June 2014). "Progressive proximal-to-distal reduction in expression of the tight junction complex in colonic epithelium of virally-suppressed HIV+ individuals". PLOS Pathogens. 10 (6): e1004198. doi:10.1371/journal.ppat.1004198. PMC 4072797. PMID 24968145.
  100. ^ "Stanford University HIV Drug Resistance Database". Retrieved 2014-04-13.
  101. ^ Aves T, Tambe J, Siemieniuk RA, Mbuagbaw L, et al. (Cochrane Infectious Diseases Group) (November 2018). "Antiretroviral resistance testing in HIV-positive people". The Cochrane Database of Systematic Reviews. 11: CD006495. doi:10.1002/14651858.CD006495.pub5. PMC 6517236. PMID 30411789.
  102. ^ Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, et al. (March 2000). "HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort". Antiviral Therapy. 5 (1): 49–55. doi:10.1177/135965350000500113. PMID 10846593. S2CID 33402816.
  103. ^ a b c Simon V, Ho DD, Abdool Karim Q (August 2006). "HIV/AIDS epidemiology, pathogenesis, prevention, and treatment". Lancet. 368 (9534): 489–504. doi:10.1016/S0140-6736(06)69157-5. PMC 2913538. PMID 16890836.
  104. ^ Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA (November 2001). "Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase". The Journal of Biological Chemistry. 276 (44): 40847–57. doi:10.1074/jbc.M106743200. PMID 11526116.
  105. ^ Birkus G, Hitchcock MJ, Cihlar T (March 2002). "Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors". Antimicrobial Agents and Chemotherapy. 46 (3): 716–23. doi:10.1128/aac.46.3.716-723.2002. PMC 127499. PMID 11850253.
  106. ^ Hulgan T, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, et al. (27 August 2012). "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384". PLOS ONE. 7 (8): e43803. Bibcode:2012PLoSO...743803H. doi:10.1371/journal.pone.0043803. PMC 3433792. PMID 22970105.
  107. ^ Guzmán-Fulgencio M, Berenguer J, Micheloud D, Fernández-Rodríguez A, García-Álvarez M, Jiménez-Sousa MA, et al. (October 2013). "European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy". The Journal of Antimicrobial Chemotherapy. 68 (10): 2349–2357. doi:10.1093/jac/dkt206. PMID 23749950.
  108. ^ Hart AB, Samuels DC, Hulgan T (October 2013). "The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy". AIDS Reviews. 15 (4): 213–220. PMC 4001077. PMID 24322381.
  109. ^ Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy
  110. ^ Boelsterli UA, Lim PL (April 2007). "Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?". Toxicology and Applied Pharmacology. 220 (1): 92–107. doi:10.1016/j.taap.2006.12.013. PMID 17275868.
  111. ^ Usach I, Melis V, Peris JE (September 2013). "Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability". Journal of the International AIDS Society. 16 (1): 18567. doi:10.7448/ias.16.1.18567. PMC 3764307. PMID 24008177.
  112. ^ Walmsley S (June 2007). "Protease inhibitor-based regimens for HIV therapy: safety and efficacy". Journal of Acquired Immune Deficiency Syndromes. 45 Suppl 1 (Supplement 1): S5–13, quiz S28–31. doi:10.1097/QAI.0b013e3180600709. PMID 17525691. S2CID 3113311.
  113. ^ Lee FJ, Carr A (September 2012). "Tolerability of HIV integrase inhibitors". Current Opinion in HIV and AIDS. 7 (5): 422–8. doi:10.1097/COH.0b013e328356682a. PMID 22886031. S2CID 29497910.
  114. ^ Bell DM (May 1997). "Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview". The American Journal of Medicine. 102 (5B): 9–15. doi:10.1016/s0002-9343(97)89441-7. PMID 9845490.
  115. ^ Ippolito G, Puro V, De Carli G (June 1993). "The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection". Archives of Internal Medicine. 153 (12): 1451–8. doi:10.1001/archinte.1993.00410120035005. PMID 8512436.
  116. ^ a b c Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, Gomaa A, Panlilio AL (September 2013). "Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis". Infection Control and Hospital Epidemiology. 34 (9): 875–92. doi:10.1086/672271. JSTOR 672271. PMID 23917901. S2CID 17032413.
  117. ^ Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. (November 1997). "A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group". The New England Journal of Medicine. 337 (21): 1485–90. doi:10.1056/NEJM199711203372101. PMID 9366579.
  118. ^ Glynn JR, Buvé A, Caraël M, Kahindo M, Macauley IB, Musonda RM, Jungmann E, Tembo F, Zekeng L (December 2000). "Decreased fertility among HIV-1-infected women attending antenatal clinics in three African cities". Journal of Acquired Immune Deficiency Syndromes. 25 (4): 345–52. doi:10.1097/00126334-200012010-00008. PMID 11114835. S2CID 22980353.
  119. ^ a b Savasi V, Mandia L, Laoreti A, Cetin I (2012). "Reproductive assistance in HIV serodiscordant couples". Human Reproduction Update. 19 (2): 136–50. doi:10.1093/humupd/dms046. PMID 23146867.
  120. ^ Centers for Disease Control (CDC) (April 1990). "HIV-1 infection and artificial insemination with processed semen". MMWR. Morbidity and Mortality Weekly Report. 39 (15): 249, 255–6. PMID 2109169.
  121. ^ Savasi V, Ferrazzi E, Lanzani C, Oneta M, Parrilla B, Persico T (March 2007). "Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples". Human Reproduction. 22 (3): 772–7. doi:10.1093/humrep/del422. PMID 17107974.
  122. ^ Coutsoudis A, Kwaan L, Thomson M (October 2010). "Prevention of vertical transmission of HIV-1 in resource-limited settings". Expert Review of Anti-Infective Therapy. 8 (10): 1163–75. doi:10.1586/eri.10.94. PMID 20954881. S2CID 46624541.
  123. ^ "U.S Approves Drug to Prolong Lives of AIDS Patients". New York Times. 1987-03-21.
  124. ^ Institute of Medicine (US) Committee for the Oversight of AIDS Activities (1988). Confronting AIDS. doi:10.17226/771. ISBN 978-0-309-03879-9. PMID 25032454.
  125. ^ Moore RD, Chaisson RE (April 1996). "Natural history of opportunistic disease in an HIV-infected urban clinical cohort". Annals of Internal Medicine. 124 (7): 633–42. doi:10.7326/0003-4819-124-7-199604010-00003. PMID 8607591. S2CID 20023137.
  126. ^ Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. (September 1997). "A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team". The New England Journal of Medicine. 337 (11): 725–33. doi:10.1056/NEJM199709113371101. PMID 9287227. S2CID 24043435.
  127. ^ a b Sifris D, Myhre J (2017), When Did HAART Become ART? Change Is About More Than Just Semantics [reviewed by a board-certified physician].
  128. ^ a b c Passaes CP, Sáez-Cirión A (April 2014). "HIV cure research: advances and prospects" (PDF). Virology. 454–455: 340–52. doi:10.1016/j.virol.2014.02.021. PMID 24636252. S2CID 205649442.
  129. ^ Rosenberg T (May 29, 2011). "The Man Who Had HIV and Now Does Not". New York Magazine. Retrieved 2014-04-12.
  130. ^ Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. (February 2009). "Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation". The New England Journal of Medicine. 360 (7): 692–8. doi:10.1056/NEJMoa0802905. PMID 19213682. S2CID 14905671.
  131. ^ Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH (March 2014). "Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV". The New England Journal of Medicine. 370 (10): 901–10. doi:10.1056/NEJMoa1300662. PMC 4084652. PMID 24597865.
  132. ^ HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene Aridaman Pandit & Rob J. de Boer. Scientific Reports volume 5, Article number: 18088 (2016)
  133. ^ Senthilingam M (18 July 2016). "HIV cure study provides insight into 2008 case". CNN. Retrieved 21 July 2016.
  134. ^ Darmanin M (21 July 2016). "No trace of HIV virus after successful stem cell transplantation". UtrechtCentral.com. Retrieved 21 July 2016.
  135. ^ "2016 Towards an HIV Cure Symposium Programme. 16 & 17 July 2016" (PDF). Durban International Convention Centre (ICC), Durban, South Africa: AIDS Society (IAS). 21 June 2016. Retrieved 21 July 2016.
  136. ^ Levin, Jules (19 July 2016). "Allogeneic Stem Cell Transplantation in HIV-1 infected individuals; the EpiStem Consortium [Conference Reports for NATAP] [IAS Durban HIV cure Symposium July 16–17 2016]". National AIDS Treatment Advocacy Project (NATAP). Retrieved 23 July 2016.
  137. ^ Johnson C (5 March 2019). "A decade after the first person was cured of HIV, a second patient is in long-term remission". The Washington Post. Retrieved 5 March 2019.
  138. ^ May A (5 March 2019). "HIV patient seemingly cured in second remarkable case, London doctors report". USA Today. Retrieved 5 March 2019.
  139. ^ Kang H, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II (December 2015). "CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus". Molecular Therapy. Nucleic Acids. 4: e268. doi:10.1038/mtna.2015.42. PMID 26670276.
  140. ^ Charpentier E (April 2015). "CRISPR-Cas9: how research on a bacterial RNA-guided mechanism opened new perspectives in biotechnology and biomedicine". EMBO Molecular Medicine. 7 (4): 363–365. doi:10.15252/emmm.201504847. PMC 4403038. PMID 25796552.
  141. ^ Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. (August 2009). "HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation". Nature Medicine. 15 (8): 893–900. doi:10.1038/nm.1972. PMC 2859814. PMID 19543283.
  142. ^ McNeil, Donald (2014). "Early Treatment Is Found to Clear H.I.V. in a 2nd Baby". The New York Times.
  143. ^ Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, et al. (November 2013). "Absence of detectable HIV-1 viremia after treatment cessation in an infant". The New England Journal of Medicine. 369 (19): 1828–35. doi:10.1056/NEJMoa1302976. PMC 3954754. PMID 24152233.
  144. ^ Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM (February 2010). "Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection". PLOS ONE. 5 (2): e9390. Bibcode:2010PLoSO...5.9390A. doi:10.1371/journal.pone.0009390. PMC 2826423. PMID 20186346.
  145. ^ Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. (July 2012). "Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy". Nature. 487 (7408): 482–5. Bibcode:2012Natur.487..482A. doi:10.1038/nature11286. PMC 3704185. PMID 22837004.
  146. ^ Carcelain G, Autran B (July 2013). "Immune interventions in HIV infection". Immunological Reviews. 254 (1): 355–71. doi:10.1111/imr.12083. PMID 23772631. S2CID 34104811.
  147. ^ . www.biosantech.org. Archived from the original on 2016-06-01. Retrieved 2015-10-27.
  148. ^ Watkins JD, Lancelot S, Campbell GR, Esquieu D, de Mareuil J, Opi S, et al. (January 2006). "Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine". Retrovirology. 3: 8. doi:10.1186/1742-4690-3-8. PMC 1434768. PMID 16441880.
  149. ^ Haynes BF, Burton DR (March 2017). "Developing an HIV vaccine". Science. 355 (6330): 1129–1130. Bibcode:2017Sci...355.1129H. doi:10.1126/science.aan0662. PMC 5569908. PMID 28302812.
  150. ^ Checkley MA, Luttge BG, Freed EO (July 2011). "HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation". Journal of Molecular Biology. 410 (4): 582–608. doi:10.1016/j.jmb.2011.04.042. PMC 3139147. PMID 21762802.
  151. ^ Pardi N, Hogan MJ, Porter FW, Weissman D (April 2018). "mRNA vaccines - a new era in vaccinology". Nature Reviews. Drug Discovery. 17 (4): 261–279. doi:10.1038/nrd.2017.243. PMC 5906799. PMID 29326426.
  152. ^ Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. (March 2017). "Modified mRNA Vaccines Protect against Zika Virus Infection". Cell. 168 (6): 1114–1125.e10. doi:10.1016/j.cell.2017.02.017. PMC 5388441. PMID 28222903.
  153. ^ "The HIV Life Cycle | NIH". hivinfo.nih.gov. Retrieved 2021-11-30.
  154. ^ Fischer W, Giorgi EE, Chakraborty S, Nguyen K, Bhattacharya T, Theiler J, et al. (July 2021). "HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens". Cell Host & Microbe. 29 (7): 1093–1110. doi:10.1016/j.chom.2021.05.012. PMC 8173590. PMID 34242582.
  155. ^ Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. (April 2013). "Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus". Nature. 496 (7446): 469–476. Bibcode:2013Natur.496..469.. doi:10.1038/nature12053. PMC 3637846. PMID 23552890.
  156. ^ Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al. (November 2011). "A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield". Science. 334 (6059): 1097–1103. Bibcode:2011Sci...334.1097P. doi:10.1126/science.1213256. PMC 3280215. PMID 21998254.
  157. ^ Burton DR, Hangartner L (May 2016). "Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design". Annual Review of Immunology. 34 (1): 635–659. doi:10.1146/annurev-immunol-041015-055515. PMC 6034635. PMID 27168247.
  158. ^ McCoy LE (October 2018). "The expanding array of HIV broadly neutralizing antibodies". Retrovirology. 15 (1): 70. doi:10.1186/s12977-018-0453-y. PMC 6192334. PMID 30326938.
  159. ^ a b c Mu Z, Haynes BF, Cain DW (February 2021). "HIV mRNA Vaccines-Progress and Future Paths". Vaccines. 9 (2): 134. doi:10.3390/vaccines9020134. PMC 7915550. PMID 33562203.
  160. ^ a b "First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research". www.scripps.edu. Retrieved 2021-11-30.
  161. ^ Jones LD, Moody MA, Thompson AB (March 2020). "Innovations in HIV-1 Vaccine Design". Clinical Therapeutics. 42 (3): 499–514. doi:10.1016/j.clinthera.2020.01.009. PMC 7102617. PMID 32035643.
  162. ^ International AIDS Vaccine Initiative (2021-09-29). "A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health". ModernaTX, Inc., The University of Texas at San Antonio, George Washington University, Fred Hutchinson Cancer Research Center, Emory University. {{cite journal}}: Cite journal requires |journal= (help)
  163. ^ Kallen A, Woloshin S, Shu J, Juhl E, Schwartz L (2007-10-01). "Direct-to-consumer advertisements for HIV antiretroviral medications: a progress report". Health Affairs. 26 (5): 1392–1398. doi:10.1377/hlthaff.26.5.1392. PMID 17848450. S2CID 12536749.
  164. ^ Josefson D (May 2001). "FDA warning to manufacturers of AIDS drugs". BMJ. 322 (7295): 1143. doi:10.1136/bmj.322.7295.1143. PMC 1120280. PMID 11348904.
  165. ^ . www.who.int. Archived from the original on March 17, 2019. Retrieved 2019-03-07.
  166. ^ a b Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, et al. (October 2014). "Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population". The Lancet. HIV. 1 (1): e32-40. doi:10.1016/S2352-3018(14)70018-9. PMID 26423814.
  167. ^ a b Gakhar H, Kamali A, Holodniy M (May 2013). "Health-related quality of life assessment after antiretroviral therapy: a review of the literature". Drugs. 73 (7): 651–72. doi:10.1007/s40265-013-0040-4. PMC 4448913. PMID 23591907.
  168. ^ a b Mak WW, Poon CY, Pun LY, Cheung SF (July 2007). "Meta-analysis of stigma and mental health". Social Science & Medicine. 65 (2): 245–61. doi:10.1016/j.socscimed.2007.03.015. PMID 17462800.
  169. ^ a b Wolfe D, Carrieri MP, Shepard D (July 2010). "Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward". Lancet. 376 (9738): 355–66. doi:10.1016/S0140-6736(10)60832-X. PMID 20650513. S2CID 13205040.
  170. ^ van der Heijden I, Abrahams N, Sinclair D, et al. (Cochrane Infectious Diseases Group) (March 2017). "Psychosocial group interventions to improve psychological well-being in adults living with HIV". The Cochrane Database of Systematic Reviews. 3: CD010806. doi:10.1002/14651858.CD010806.pub2. PMC 5461871. PMID 28291302.
  171. ^ "HIV/AIDS in NYC" (PDF).
  172. ^ "Health equity". August 11, 2022 – via Wikipedia.

External links

  • HIVinfo – Comprehensive resource for HIV/AIDS treatment and clinical trial information from the U. S. Department of Health and Human Services
  • ASHM – Australian Commentary on HHS Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
  • Viral Load research papers, including effectiveness of HAART on reducing viral load
  • Current status of gene therapy strategies to treat HIV/AIDS

December 27, 2022
management, aids, management, aids, normally, includes, multiple, antiretroviral, drugs, strategy, control, infection, there, several, classes, antiretroviral, agents, that, different, stages, life, cycle, multiple, drugs, that, different, viral, targets, know. The management of HIV AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection 1 There are several classes of antiretroviral agents that act on different stages of the HIV life cycle The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy HAART HAART decreases the patient s total burden of HIV maintains function of the immune system and prevents opportunistic infections that often lead to death 2 HAART also prevents the transmission of HIV between serodiscordant same sex and opposite sex partners so long as the HIV positive partner maintains an undetectable viral load 3 Treatment has been so successful that in many parts of the world HIV has become a chronic condition in which progression to AIDS is increasingly rare Anthony Fauci head of the United States National Institute of Allergy and Infectious Diseases has written With collective and resolute action now and a steadfast commitment for years to come an AIDS free generation is indeed within reach In the same paper he noted that an estimated 700 000 lives were saved in 2010 alone by antiretroviral therapy 4 As another commentary in The Lancet noted Rather than dealing with acute and potentially life threatening complications clinicians are now confronted with managing a chronic disease that in the absence of a cure will persist for many decades 5 The United States Department of Health and Human Services and the World Health Organization 6 WHO recommend offering antiretroviral treatment to all patients with HIV 7 Because of the complexity of selecting and following a regimen the potential for side effects and the importance of taking medications regularly to prevent viral resistance such organizations emphasize the importance of involving patients in therapy choices and recommend analyzing the risks and the potential benefits 7 The WHO has defined health as more than the absence of disease For this reason many researchers have dedicated their work to better understanding the effects of HIV related stigma the barriers it creates for treatment interventions and the ways in which those barriers can be circumvented 8 9 Contents 1 Classes of medication 1 1 Entry inhibitors 1 2 Nucleoside nucleotide reverse transcriptase inhibitors 1 3 Non nucleoside reverse transcriptase inhibitors 1 4 Integrase inhibitors 1 5 Protease inhibitors 2 Combination therapy 2 1 Adjunct treatment 3 Treatment guidelines 3 1 Initiation of antiretroviral therapy 3 1 1 Treatment as prevention 3 2 Guideline sources 3 2 1 Guidelines 3 2 2 Baseline resistance 3 3 Regimens 3 4 Special populations 3 4 1 Acute infection 3 4 2 Children 3 4 3 Pregnant women 3 4 4 Older adults 3 4 5 Adults with depression 4 Concerns 5 Response to therapy 5 1 Virologic response 5 2 Immunologic response 6 Salvage therapy 7 Structured treatment interruptions 8 Adverse effects 8 1 NRTIs 8 2 NNRTIs 8 3 Protease inhibitors 8 4 Integrase inhibitors 9 Post exposure prophylaxis PEP 10 Pregnancy planning 11 History 12 Research 12 1 Patients cured of HIV infection 12 2 Viral reservoirs 12 3 Immune activation 12 4 Sequential mRNA Vaccine 13 Drug advertisements 14 Beyond medical management 15 Food insecurity 16 See also 17 References 18 External linksClasses of medication Edit Schematic description of the mechanism of the four classes of available antiretroviral drugs against HIV There are six classes of drugs which are usually used in combination to treat HIV infection Antiretroviral ARV drugs are broadly classified by the phase of the retrovirus life cycle that the drug inhibits Typical combinations include two nucleoside reverse transcriptase inhibitors NRTI as a backbone along with one non nucleoside reverse transcriptase inhibitor NNRTI protease inhibitor PI or integrase inhibitors also known as integrase nuclear strand transfer inhibitors or INSTIs as a base 7 Entry inhibitors Edit Entry inhibitors or fusion inhibitors interfere with binding fusion and entry of HIV 1 to the host cell by blocking one of several targets Maraviroc and enfuvirtide are the two available agents in this class Maraviroc works by targeting CCR5 a co receptor located on human helper T cells Caution should be used when administering this drug however due to a possible shift in tropism which allows HIV to target an alternative co receptor such as CXCR4 citation needed In rare cases individuals may have a mutation in the CCR5 delta gene which results in a nonfunctional CCR5 co receptor and in turn a means of resistance or slow progression of the disease However as mentioned previously this can be overcome if an HIV variant that targets CXCR4 becomes dominant 10 To prevent fusion of the virus with the host membrane enfuvirtide can be used Enfuvirtide is a peptide drug that must be injected and acts by interacting with the N terminal heptad repeat of gp41 of HIV to form an inactive hetero six helix bundle therefore preventing infection of host cells 11 Nucleoside nucleotide reverse transcriptase inhibitors Edit Nucleoside reverse transcriptase inhibitors NRTI and nucleotide reverse transcriptase inhibitors NtRTI are nucleoside and nucleotide analogues which inhibit reverse transcription HIV is an RNA virus so it can not be integrated into the DNA in the nucleus of the human cell unless it is first reverse transcribed into DNA Since the conversion of RNA to DNA is not naturally done in the mammalian cell it is performed by a viral protein reverse transcriptase which makes it a selective target for inhibition NRTIs are chain terminators Once NRTIs are incorporated into the DNA chain their lack of a 3 OH group prevents the subsequent incorporation of other nucleosides Both NRTIs and NtRTIs act as competitive substrate inhibitors Examples of NRTIs include zidovudine abacavir lamivudine emtricitabine and of NtRTIs tenofovir and adefovir 12 Non nucleoside reverse transcriptase inhibitors Edit Non nucleoside reverse transcriptase inhibitors NNRTI inhibit reverse transcriptase by binding to an allosteric site of the enzyme NNRTIs act as non competitive inhibitors of reverse transcriptase NNRTIs affect the handling of substrate nucleotides by reverse transcriptase by binding near the active site NNRTIs can be further classified into 1st generation and 2nd generation NNRTIs 1st generation NNRTIs include nevirapine and efavirenz 2nd generation NNRTIs are etravirine and rilpivirine 12 HIV 2 is naturally resistant to NNRTIs 13 Integrase inhibitors Edit Integrase inhibitors also known as integrase nuclear strand transfer inhibitors or INSTIs inhibit the viral enzyme integrase which is responsible for integration of viral DNA into the DNA of the infected cell There are several integrase inhibitors under clinical trial when and raltegravir became the first to receive FDA approval in October 2007 Raltegravir has two metal binding groups that compete for substrate with two Mg2 ions at the metal binding site of integrase As of early 2022 four other clinically approved integrase inhibitors are elvitegravir dolutegravir bictegravir and cabotegravir 14 Protease inhibitors Edit Protease inhibitors block the viral protease enzyme necessary to produce mature virions upon budding from the host membrane Particularly these drugs prevent the cleavage of gag and gag pol precursor proteins 15 Virus particles produced in the presence of protease inhibitors are defective and mostly non infectious Examples of HIV protease inhibitors are lopinavir indinavir nelfinavir amprenavir and ritonavir Darunavir and atazanavir are recommended as first line therapy choices 7 Maturation inhibitors have a similar effect by binding to gag but development of two experimental drugs in this class bevirimat and vivecon was halted in 2010 16 Resistance to some protease inhibitors is high Second generation drugs have been developed that are effective against otherwise resistant HIV variants 15 Combination therapy EditThe life cycle of HIV can be as short as about 1 5 days from viral entry into a cell through replication assembly and release of additional viruses to infection of other cells 17 HIV lacks proofreading enzymes to correct errors made when it converts its RNA into DNA via reverse transcription Its short life cycle and high error rate cause the virus to mutate very rapidly resulting in a high genetic variability Most of the mutations either are inferior to the parent virus often lacking the ability to reproduce at all or convey no advantage but some of them have a natural selection superiority to their parent and can enable them to slip past defenses such as the human immune system and antiretroviral drugs The more active copies of the virus the greater the possibility that one resistant to antiretroviral drugs will be made 18 When antiretroviral drugs are used improperly multi drug resistant strains can become the dominant genotypes very rapidly In the era before multiple drug classes were available pre 1997 the reverse transcriptase inhibitors zidovudine didanosine zalcitabine stavudine and lamivudine were used serially or in combination leading to the development of multi drug resistant mutations 19 In contrast antiretroviral combination therapy defends against resistance by creating multiple obstacles to HIV replication This keeps the number of viral copies low and reduces the possibility of a superior mutation 18 If a mutation that conveys resistance to one of the drugs arises the other drugs continue to suppress reproduction of that mutation With rare exceptions no individual antiretroviral drug has been demonstrated to suppress an HIV infection for long these agents must be taken in combinations in order to have a lasting effect As a result the standard of care is to use combinations of antiretroviral drugs 7 Combinations usually consist of three drugs from at least two different classes 7 This three drug combination is commonly known as a triple cocktail 20 Combinations of antiretrovirals are subject to positive and negative synergies which limits the number of useful combinations citation needed Because of HIV s tendency to mutate when patients who have started an antiretrovial regimen fail to take it regularly resistance can develop 21 On the other hand patients who take their medications regularly can stay on one regimen without developing resistance 21 This greatly increases life expectancy and leaves more drugs available to the individual should the need arise citation needed A 2016 advertisement from NIAID promoting the advancement of single pill antiretroviral drug combinations In recent years when drug companies have worked together to combine these complex regimens into single pill fixed dose combinations 22 More than 20 antiretroviral fixed dose combinations have been developed This greatly increases the ease with which they can be taken which in turn increases the consistency with which medication is taken adherence 23 and thus their effectiveness over the long term Adjunct treatment Edit Although antiretroviral therapy has helped to improve the quality of life of people living with HIV there is still a need to explore other ways to further address the disease burden One such potential strategy that was investigated was to add interleukin 2 as an adjunct to antiretroviral therapy for adults with HIV A Cochrane review included 25 randomized controlled trials that were conducted across six countries 24 The researchers found that interleukin 2 increases the CD4 immune cells but does not make a difference in terms of death and incidence of other infections Furthermore there is probably an increase in side effects with interleukin 2 The findings of this review do not support the use of interleukin 2 as an add on treatment to antiretroviral therapy for adults with HIV citation needed Treatment guidelines EditInitiation of antiretroviral therapy Edit Antiretroviral drug treatment guidelines have changed over time Before 1987 no antiretroviral drugs were available and treatment consisted of treating complications from opportunistic infections and malignancies After antiretroviral medications were introduced most clinicians agreed that HIV positive patients with low CD4 counts should be treated but no consensus formed as to whether to treat patients with high CD4 counts 25 In April 1995 Merck and the National Institute of Allergy and Infectious Diseases began recruiting patients for a trial examining the effects of a three drug combination of the protease inhibitor indinavir and two nucleoside analogs 26 illustrating the substantial benefit of combining 2 NRTIs with a new class of antiretrovirals protease inhibitors namely indinavir Later that year David Ho became an advocate of this hit hard hit early approach with aggressive treatment with multiple antiretrovirals early in the course of the infection 27 Later reviews in the late 90s and early 2000s noted that this approach of hit hard hit early ran significant risks of increasing side effects and development of multidrug resistance and this approach was largely abandoned The only consensus was on treating patients with advanced immunosuppression CD4 counts less than 350 mL 28 Treatment with antiretrovirals was expensive at the time ranging from 10 000 to 15 000 a year 29 The timing of when to start therapy has continued to be a core controversy within the medical community though recent when studies have led to more clarity The NA ACCORD 30 study observed patients who started antiretroviral therapy either at a CD4 count of less than 500 versus less than 350 and showed that patients who started ART at lower CD4 counts had a 69 increase in the risk of death 30 In 2015 the START 31 and TEMPRANO 32 studies both showed that patients lived longer if they started antiretrovirals at the time of their diagnosis rather than waiting for their CD4 counts to drop to a specified level Other arguments for starting therapy earlier are that people who start therapy later have been shown to have less recovery of their immune systems 33 and higher CD4 counts are associated with less cancer 34 The European Medicines Agency EMA has recommended the granting of marketing authorizations for two new antiretroviral ARV medicines rilpivirine Rekambys and cabotegravir Vocabria to be used together for the treatment of people with human immunodeficiency virus type 1 HIV 1 infection 35 The two medicines are the first ARVs that come in a long acting injectable formulation 35 This means that instead of daily pills people receive intramuscular injections monthly or every two months 35 The combination of Rekambys and Vocabria injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood viral load less than 50 copies ml with their current ARV treatment and when the virus has not developed resistance to certain class of anti HIV medicines called non nucleoside reverse transcriptase inhibitors NNRTIs and integrase strand transfer inhibitors INIs 35 Treatment as prevention Edit A separate argument for starting antiretroviral therapy that has gained more prominence is its effect on HIV transmission ART reduces the amount of virus in the blood and genital secretions 36 37 This has been shown to lead to dramatically reduced transmission of HIV when one partner with a suppressed viral load lt 50 copies ml has sex with a partner who is HIV negative In clinical trial HPTN 052 1763 serodiscordant heterosexual couples in 9 countries were planned to be followed for at least 10 years with both groups receiving education on preventing HIV transmission and condoms but only one group getting ART The study was stopped early after 1 7 years for ethical reasons when it became clear that antiviral treatment provided significant protection Of the 28 couples where cross infection had occurred all but one had taken place in the control group consistent with a 96 reduction in risk of transmission while on ART The single transmission in the experimental group occurred early after starting ART before viral load was likely to be suppressed 38 Pre exposure prophylaxis PrEP provides HIV negative individuals with medication in conjunction with safer sex education and regular HIV STI screenings in order to reduce the risk of acquiring HIV 39 In 2011 the journal Science gave the Breakthrough of the Year award to treatment as prevention 40 In July 2016 a consensus document was created by the Prevention Access Campaign which has been endorsed by over 400 organisations in 58 countries The consensus document states that the risk of HIV transmission from a person living with HIV who has been undetectable for a minimum of six months is negligible to non existent with negligible being defined as so small or unimportant to be not worth considering The Chair of the British HIV Association BHIVA Chloe Orkin stated in July 2017 that there should be no doubt about the clear and simple message that a person with sustained undetectable levels of HIV virus in their blood cannot transmit HIV to their sexual partners 41 Furthermore the PARTNER study 42 which ran from 2010 to 2014 enrolled 1166 serodiscordant couples where one partner is HIV positive and the other is negative in a study that found that the estimated rate of transmission through any condomless sex with the HIV positive partner taking ART with an HIV load less than 200 copies ml was zero 42 In summary as the WHO HIV treatment guidelines state The ARV regimens now available even in the poorest countries are safer simpler more effective and more affordable than ever before 43 There is a consensus among experts that once initiated antiretroviral therapy should never be stopped This is because the selection pressure of incomplete suppression of viral replication in the presence of drug therapy causes the more drug sensitive strains to be selectively inhibited This allows the drug resistant strains to become dominant This in turn makes it harder to treat the infected individual as well as anyone else they infect 7 One trial showed higher rates of opportunistic infections cancers heart attacks and death in patients who periodically interrupted their ART 44 45 Guideline sources Edit There are several treatment guidelines for HIV 1 infected adults in the developed world that is those countries with access to all or most therapies and laboratory tests In the United States there are both the International AIDS Society USA IAS USA a 501 c 3 not for profit organization in the US 46 as well as the US government s Department of Health and Human Services guidelines 7 In Europe there are the European AIDS Clinical Society guidelines 47 For resource limited countries most national guidelines closely follow the World Health Organization WHO guidelines 6 Guidelines Edit The guidelines use new criteria to consider starting HAART as described below However there remain a range of views on this subject and the decision of whether to commence treatment ultimately rests with the patient and his or her doctor citation needed The US DHHS guidelines published April 8 2015 state citation needed Antiretroviral therapy ART is recommended for all HIV infected individuals to reduce the risk of disease progression ART also is recommended for HIV infected individuals for the prevention of transmission of HIV Patients starting ART should be willing and able to commit to treatment and understand the benefits and risks of therapy and the importance of adherence Patients may choose to postpone therapy and providers on a case by case basis may elect to defer therapy on the basis of clinical and or psychosocial factors The newest WHO guidelines dated September 30 2015 now agree and state 6 Antiretroviral therapy ART should be initiated in everyone living with HIV at any CD4 cell countBaseline resistance Edit Baseline resistance is the presence of resistance mutations in patients who have never been treated before for HIV In countries with a high rate of baseline resistance resistance testing is recommended before starting treatment or if the initiation of treatment is urgent then a best guess treatment regimen should be started which is then modified on the basis of resistance testing 13 In the UK there is 11 8 medium to high level resistance at baseline to the combination of efavirenz zidovudine lamivudine and 6 4 medium to high level resistance to stavudine lamivudine nevirapine 48 In the US 10 8 of one cohort of patients who had never been on ART before had at least one resistance mutation in 2005 49 Various surveys in different parts of the world have shown increasing or stable rates of baseline resistance as the era of effective HIV therapy continues 50 51 52 53 With baseline resistance testing a combination of antiretrovirals that are likely to be effective can be customized for each patient citation needed Regimens Edit Most HAART regimens consist of three drugs 2 NRTIs backbone a PI NNRTI INSTI base Initial regimens use first line drugs with a high efficacy and low side effect profile The US DHHS preferred initial regimens for adults and adolescents in the United States as of April 2015 are 7 tenofovir emtricitabine and raltegravir an integrase inhibitor tenofovir emtricitabine and dolutegravir an integrase inhibitor abacavir lamivudine two NRTIs and dolutegravir for patients who have been tested negative for the HLA B 5701 gene allele tenofovir emtricitabine elvitegravir an integrase inhibitor and cobicistat inhibiting metabolism of the former in patients with good kidney function gfr gt 70 tenofovir emtricitabine ritonavir and darunavir both latter are protease inhibitors Both efavirenz and nevirapine showed similar benefits when combined with NRTI respectively 54 In the case of the protease inhibitor based regimens ritonavir is used at low doses to inhibit cytochrome p450 enzymes and boost the levels of other protease inhibitors rather than for its direct antiviral effect This boosting effect allows them to be taken less frequently throughout the day 55 Cobicistat is used with elvitegravir for a similar effect but does not have any direct antiviral effect itself 56 The WHO preferred initial regimen for adults and adolescents as of June 30 2013 is 43 tenofovir lamivudine or emtricitabine efavirenzSpecial populations Edit Acute infection Edit In the first six months after infection HIV viral loads tend to be elevated and people are more often symptomatic than in later latent phases of HIV disease There may be special benefits to starting antiretroviral therapy early during this acute phase including lowering the viral set point or baseline viral load reduce the mutation rate of the virus and reduce the size of the viral reservoir See section below on viral reservoirs 7 The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed the time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped 57 Since viral loads are usually very high during acute infection this period carries an estimated 26 times higher risk of transmission 58 By treating acutely infected patients it is presumed that it could have a significant impact on decreasing overall HIV transmission rates since lower viral loads are associated with lower risk of transmission See section on treatment as prevention However an overall benefit has not been proven and has to be balanced with the risks of HIV treatment Therapy during acute infection carries a grade BII recommendation from the US DHHS 7 Children Edit HIV can be especially harmful to infants and children with one study in Africa showing that 52 of untreated children born with HIV had died by age 2 59 By five years old the risk of disease and death from HIV starts to approach that of young adults The WHO recommends treating all children less than 5 years old and starting all children older than 5 with stage 3 or 4 disease or CD4 lt 500 cells ml 43 DHHS guidelines are more complicated but recommend starting all children less than 12 months old and children of any age who have symptoms 60 As for which antiretrovirals to use this is complicated by the fact that many children who are born to mothers with HIV are given a single dose of nevirapine an NNRTI at the time of birth to prevent transmission If this fails it can lead to NNRTI resistance 61 Also a large study in Africa and India found that a PI based regimen was superior to an NNRTI based regimen in children less than 3 years who had never been exposed to NNRTIs in the past 62 Thus the WHO recommends PI based regimens for children less than 3 The WHO recommends for children less than 3 years 43 abacavir or zidovudine lamivudine lopinivir ritonivirand for children 3 years to less than 10 years and adolescents lt 35 kilograms abacavir lamivudine efavirenzUS DHHS guidelines are similar but include PI based options for children gt 3 years old 60 A systematic review assessed the effects and safety of abacavir containing regimens as first line therapy for children between 1 month and 18 years of age when compared to regimens with other NRTIs 63 This review included two trials and two observational studies with almost eleven thousand HIV infected children and adolescents They measured virologic suppression death and adverse events The authors found that there is no meaningful difference between abacavir containing regimens and other NRTI containing regimens The evidence is of low to moderate quality and therefore it is likely that future research may change these findings citation needed Pregnant women Edit Main articles HIV and pregnancy and Breastfeeding by HIV infected mothers The goals of treatment for pregnant women include the same benefits to the mother as in other infected adults as well as prevention of transmission to her child The risk of transmission from mother to child is proportional to the plasma viral load of the mother Untreated mothers with a viral load gt 100 000 copies ml have a transmission risk of over 50 64 The risk when viral loads are lt 1000 copies ml are less than 1 65 ART for mothers both before and during delivery and to mothers and infants after delivery are recommended to substantially reduce the risk of transmission 66 The mode of delivery is also important with a planned Caesarian section having a lower risk than vaginal delivery or emergency Caesarian section 65 HIV can also be detected in breast milk of infected mothers and transmitted through breast feeding 67 The WHO balances the low risk of transmission through breast feeding from women who are on ART with the benefits of breastfeeding against diarrhea pneumonia and malnutrition It also strongly recommends that breastfeeding infants receive prophylactic ART 43 In the US the DHHS recommends against women with HIV breastfeeding 66 Older adults Edit With improvements in HIV therapy several studies now estimate that patients on treatment in high income countries can expect a normal life expectancy 68 69 This means that a higher proportion of people living with HIV are now older and research is ongoing into the unique aspects of HIV infection in the older adult There is data that older people with HIV have a blunted CD4 response to therapy but are more likely to achieve undetectable viral levels 70 However not all studies have seen a difference in response to therapy 71 The guidelines do not have separate treatment recommendations for older adults but it is important to take into account that older patients are more likely to be on multiple non HIV medications and consider drug interactions with any potential HIV medications 72 There are also increased rates of HIV associated non AIDS conditions HANA such as heart disease liver disease and dementia that are multifactorial complications from HIV associated behaviors coinfections like hepatitis B hepatitis C and human papilloma virus HPV as well as HIV treatment 72 Adults with depression Edit Many factors may contribute to depression in adults living with HIV such as the effects of the virus on the brain other infections or tumours antiretroviral drugs and other medical treatment 73 Rates of major depression are higher in people living with HIV compared to the general population and this may negatively influence antiretroviral treatment In a systematic review Cochrane researchers assessed whether giving antidepressants to adults living with both HIV and depression may improve depression 73 Ten trials of which eight were done in high income countries with 709 participants were included Results indicated that antidepressants may be better in improving depression compared to placebo but the quality of the evidence is low and future research is likely to impact on the findings citation needed Concerns EditThere are several concerns about antiretroviral regimens that should be addressed before initiating Intolerance The drugs can have serious side effects which can lead to harm as well as keep patients from taking their medications regularly Resistance Not taking medication consistently can lead to low blood levels that foster drug resistance 74 Cost The WHO maintains a database of world ART costs 75 which have dropped dramatically in recent when years as more first line drugs have gone off patent 76 A one pill once a day combination therapy has been introduced in South Africa for as little as 10 per patient per month 77 One 2013 study estimated an overall cost savings to ART therapy in South Africa given reduced transmission 78 In the United States new on patent regimens can cost up to 28 500 per patient per year 79 80 Public health Individuals who fail to use antiretrovirals as directed can develop multi drug resistant strains which can be passed onto others 81 Response to therapy EditVirologic response Edit Suppressing the viral load to undetectable levels lt 50 copies per ml is the primary goal of ART 55 This should happen by 24 weeks after starting combination therapy 82 Viral load monitoring is the most important predictor of response to treatment with ART 83 Lack of viral load suppression on ART is termed virologic failure Levels higher than 200 copies per ml is considered virologic failure and should prompt further testing for potential viral resistance 7 Research has shown that people with an undetectable viral load are unable to transmit the virus through condomless sex with a partner of either gender The Swiss Statement of 2008 described the chance of transmission as very low or negligible 84 but multiple studies have since shown that this mode of sexual transmission is impossible where the HIV positive person has a consistently undetectable viral load This discovery has led to the formation of the Prevention Access Campaign are their U U or Undetectable Untransmittable public information strategy 85 86 an approach that has gained widespread support amongst HIV AIDS related medical charitable and research organisations 41 The studies demonstrating that U U is an effective strategy for preventing HIV transmission in serodiscordant couples so long as the partner living with HIV has a durably suppressed viral load include 87 Opposites Attract 88 PARTNER 1 42 PARTNER 2 89 90 for male male couples 87 and HPTN052 91 for heterosexual couples 87 In these studies couples where one partner was HIV positive and one partner was HIV negative were enrolled and regular HIV testing completed In total from the four studies 4097 couples were enrolled over four continents and 151 880 acts of condomless sex were reported there were zero phylogenetically linked transmissions of HIV where the positive partner had an undetectable viral load 92 Following this the U U consensus statement advocating the use of zero risk was signed by hundreds of individuals and organisations including the US CDC British HIV Association and The Lancet medical journal 41 The importance of the final results of the PARTNER 2 study were described by the medical director of the Terrence Higgins Trust as impossible to overstate while lead author Alison Rodger declared that the message that undetectable viral load makes HIV untransmittable can help end the HIV pandemic by preventing HIV transmission 93 The authors summarised their findings in The Lancet as follows 89 Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero Our findings support the message of the U U undetectable equals untransmittable campaign and the benefits of early testing and treatment for HIV 89 This result is consistent with the conclusion presented by Anthony S Fauci the Director of the National Institute of Allergy and Infectious Diseases for the U S National Institutes of Health and his team in a viewpoint published in the Journal of the American Medical Association that U U is an effective HIV prevention method when an undetectable viral load is maintained 3 87 Immunologic response Edit CD4 cell counts are another key measure of immune status and ART effectiveness 82 CD4 counts should rise 50 to 100 cells per ml in the first year of therapy 55 There can be substantial fluctuation in CD4 counts of up to 25 based on the time of day or concomitant infections 94 In one long term study the majority of increase in CD4 cell counts was in the first two years after starting ART with little increase afterwards This study also found that patients who began ART at lower CD4 counts continued to have lower CD4 counts than those who started at higher CD4 counts 95 When viral suppression on ART is achieved but without a corresponding increase in CD4 counts it can be termed immunologic nonresponse or immunologic failure While this is predictive of worse outcomes there is no consensus on how to adjust therapy to immunologic failure and whether switching therapy is beneficial DHHS guidelines do not recommend switching an otherwise suppressive regimen 7 96 Innate lymphoid cells ILC are another class of immune cell that is depleted during HIV infection However if ART is initiated before this depletion at around 7 days post infection ILC levels can be maintained While CD4 cell counts typically replenish after effective ART ILCs depletion is irreversible with ART initiated after the depletion despite suppression of viremia 97 Since one of the roles of ILCs is to regulate the immune response to commensal bacteria and to maintain an effective gut barrier 98 it has been hypothesized that the irreversible depletion of ILCs plays a role in the weakened gut barrier of HIV patients even after successful ART 99 Salvage therapy EditIn patients who have persistently detectable viral loads while taking ART tests can be done to investigate whether there is drug resistance Most commonly a genotype is sequenced which can be compared with databases of other HIV viral genotypes and resistance profiles to predict response to therapy 100 Resistance testing may improve virological outcomes in those who have treatment failures However there is lack of evidence of effectiveness of such testing in those who have not done any treatment before 101 If there is extensive resistance a phenotypic test of a patient s virus against a range of drug concentrations can be performed but is expensive and can take several weeks so genotypes are generally preferred 7 Using information from a genotype or phenotype a regimen of 3 drugs from at least 2 classes is constructed that will have the highest probability of suppressing the virus If a regimen cannot be constructed from recommended first line agents it is termed salvage therapy and when 6 or more drugs are needed it is termed mega HAART 102 Structured treatment interruptions EditDrug holidays or structured treatment interruptions are intentional discontinuations of antiretroviral drug treatment As mentioned above randomized controlled studies of structured treatment interruptions have shown higher rates of opportunistic infections cancers heart attacks and death in patients who took drug holidays 44 45 103 With the exception of post exposure prophylaxis PEP treatment guidelines do not call for the interruption of drug therapy once it has been initiated 7 43 82 103 Adverse effects EditEach class and individual antiretroviral carries unique risks of adverse side effects NRTIs Edit The NRTIs can interfere with mitochondrial DNA synthesis and lead to high levels of lactate and lactic acidosis liver steatosis peripheral neuropathy myopathy and lipoatrophy 55 First line NRTIs such as lamivudine emtrictabine tenofovir and abacavir are less likely to cause mitochondrial dysfunction 104 105 Mitochondrial Haplogroups mtDNA non pathologic mutations inherited from the maternal line have been linked to the efficacy of CD4 count following ART 106 107 108 109 Idiosyncratic toxicity with mtDNA haplogroup is also well studied Boeisteril et al 2007 110 NNRTIs Edit NNRTIs are generally safe and well tolerated The main reason for discontinuation of efavirenz is neuro psychiatric effects including suicidal ideation Nevirapine can cause severe hepatotoxicity especially in women with high CD4 counts 111 Protease inhibitors Edit Protease inhibitors PIs are often given with ritonavir a strong inhibitor of cytochrome P450 enzymes leading to numerous drug drug interactions They are also associated with lipodystrophy elevated triglycerides and elevated risk of heart attack 112 Integrase inhibitors Edit Integrase inhibitors INSTIs are among the best tolerated of the antiretrovirals with excellent short and medium term outcomes Given their relatively new development there is less long term safety data They are associated with an increase in creatinine kinase levels and rarely myopathy 113 Post exposure prophylaxis PEP EditFurther information Post exposure prophylaxis HIV When people are exposed to HIV positive infectious bodily fluids either through skin puncture contact with mucous membranes or contact with damaged skin they are at risk for acquiring HIV Pooled estimates give a risk of transmission with puncture exposures of 0 3 114 and mucous membrane exposures 0 63 115 United States guidelines state that feces nasal secretions saliva sputum sweat tears urine and vomitus are not considered potentially infectious unless they are visibly bloody 116 Given the rare nature of these events rigorous study of the protective abilities of antiretrovirals are limited but do suggest that taking antiretrovirals afterwards can prevent transmission 117 It is unknown if three medications are better than two The sooner after exposure that ART is started the better but after what period they become ineffective is unknown with the US Public Health Service Guidelines recommending starting prophylaxis up to a week after exposure 116 They also recommend treating for a duration of four weeks based on animal studies Their recommended regimen is emtricitabine tenofovir raltegravir an INSTI The rationale for this regimen is that it is tolerable potent and conveniently administered and it has been associated with minimal drug interactions 116 People who are exposed to HIV should have follow up HIV testing at six 12 and 24 weeks citation needed Pregnancy planning EditFurther information HIV and pregnancy Women with HIV have been shown to have decreased fertility which can affect available reproductive options 118 In cases where the woman is HIV negative and the man is HIV positive the primary assisted reproductive method used to prevent HIV transmission is sperm washing followed by intrauterine insemination IUI or in vitro fertilization IVF Preferably this is done after the man has achieved an undetectable plasma viral load 119 In the past there have been cases of HIV transmission to an HIV negative partner through processed artificial insemination 120 but a large modern series in which followed 741 couples where the man had a stable viral load and semen samples were tested for HIV 1 there were no cases of HIV transmission 121 For cases where the woman is HIV positive and the man is HIV negative the usual method is artificial insemination 119 With appropriate treatment the risk of mother to child infection can be reduced to below 1 122 History EditSeveral buyers clubs sprang up since 1986 to combat HIV The drug zidovudine AZT a nucleoside reverse transcriptase inhibitor NRTI was not effective on its own It was approved by the US FDA in 1987 123 The FDA bypassed stages of its review for safety and effectiveness in order to distribute this drug earlier 124 Subsequently several more NRTIs were developed but even in combination were unable to suppress the virus for long periods of time and patients still inevitably died 125 To distinguish from this early antiretroviral therapy ART the term highly active antiretroviral therapy HAART was introduced In 1996 two sequential publications in The New England Journal of Medicine by Hammer and colleagues 126 and Gulick and colleagues 26 illustrated the substantial benefit of combining 2 NRTIs with a new class of antiretrovirals protease inhibitors namely indinavir This concept of 3 drug therapy was quickly incorporated into clinical practice and rapidly showed impressive benefit with a 60 to 80 decline in rates of AIDS death and hospitalization 2 As HAART became widespread fixed dose combinations were made available to ease the administration Later the term combination antiretroviral therapy cART gained favor with some physicians as a more accurate name not conveying to patients any misguided idea of the nature of the therapy 127 Today multidrug highly effective regimens are long since the default in ART which is why they are increasingly called simply ART instead of HAART or cART 127 This retronymic process is linguistically comparable to the way that the words electronic computer and digital computer at first were needed to make useful distinctions in computing technology but with the later irrelevance of the distinction computer alone now covers their meaning Thus as all computers are digital now so all ART is combination ART now However the names HAART and cART reinforced by thousands of earlier mentions in medical literature still being regularly cited also remain in use citation needed Research EditPeople living with HIV can expect to live a nearly normal life span if able to achieve durable viral suppression on combination antiretroviral therapy However this requires lifelong medication and will still have higher rates of cardiovascular kidney liver and neurologic disease 128 This has prompted further research towards a cure for HIV Patients cured of HIV infection Edit The so called Berlin patient has been potentially cured of HIV infection and has been off of treatment since 2006 with no detectable virus 129 This was achieved through two bone marrow transplants that replaced his immune system with a donor s that did not have the CCR5 cell surface receptor which is needed for some variants of HIV to enter a cell 130 Bone marrow transplants carry their own significant risks including potential death and was only attempted because it was necessary to treat a blood cancer he had Attempts to replicate this have not been successful and given the risks expense and rarity of CCR5 negative donors bone marrow transplant is not seen as a mainstream option 128 It has inspired research into other methods to try to block CCR5 expression through gene therapy A procedure zinc finger nuclease based gene knockout has been used in a Phase I trial of 12 humans and led to an increase in CD4 count and decrease in their viral load while off antiretroviral treatment 131 Attempt to reproduce this failed in 2016 Analysis of the failure showed that gene therapy only successfully treats 11 28 of cells leaving the majority of CD4 cells capable of being infected The analysis found that only patients where less than 40 of cells were infected had reduced viral load The Gene therapy was not effective if the native CD4 cells remained This is the main limitation which must be overcome for this treatment to become effective 132 After the Berlin patient two additional patients with both HIV infection and cancer were reported to have no traceable HIV virus after successful stem cell transplants Virologist Annemarie Wensing of the University Medical Center Utrecht announced this development during her presentation at the 2016 Towards an HIV Cure symposium 133 134 135 However these two patients are still on antiretroviral therapy which is not the case for the Berlin patient Therefore it is not known whether or not the two patients are cured of HIV infection The cure might be confirmed if the therapy were to be stopped and no viral rebound occurred 136 In March 2019 a second patient referred to as the London Patient was confirmed to be in complete remission of HIV Like the Berlin Patient the London Patient received a bone marrow transplant from a donor who has the same CCR5 mutation He has been off antiviral drugs since September 2017 indicating the Berlin Patient was not a one off 137 138 Alternative approaches aiming to mimic one s biological immunity to HIV through the absence or mutation of the CCR5 gene is being conducted in current research efforts The efforts of which are done through the introduction of induced pluripotent stem cells that have been CCR5 disrupted through the CRISPR Cas9 gene editing system 139 140 Viral reservoirs Edit The main obstacle to complete elimination of HIV infection by conventional antiretroviral therapy is that HIV is able to integrate itself into the DNA of host cells and rest in a latent state while antiretrovirals only attack actively replicating HIV The cells in which HIV lies dormant are called the viral reservoir and one of the main sources is thought to be central memory and transitional memory CD4 T cells 141 In 2014 there were reports of the cure of HIV in two infants 142 presumably due to the fact that treatment was initiated within hours of infection preventing HIV from establishing a deep reservoir 143 There is work being done when to try to activate reservoir cells into replication so that the virus is forced out of latency and can be attacked by antiretrovirals and the host immune system Targets include histone deacetylase HDAC which represses transcription and if inhibited can lead to increased cell activation The HDAC inhibitors valproic acid and vorinostat have been used in human trials with only preliminary results so far 144 145 Immune activation Edit Even with all latent virus deactivated it is thought that a vigorous immune response will need to be induced to clear all the remaining infected cells 128 Strategies include using cytokines to restore CD4 cell counts as well as therapeutic vaccines to prime immune responses 146 One such candidate vaccine is Tat Oyi developed by Biosantech 147 This vaccine is based on the HIV protein tat Animal models have shown the generation of neutralizing antibodies and lower levels of HIV viremia 148 Sequential mRNA Vaccine Edit HIV vaccine development is an active area of research and an important tool for managing the global AIDS epidemic Research into a vaccine for HIV has been ongoing for decades with no lasting success for preventing infection 149 The rapid development though of mRNA vaccines to deal with the COVID 19 pandemic may provide a new path forward citation needed Like SARS CoV 2 the virus that causes COVID 19 HIV has a spike protein In retroviruses like HIV the spike protein is formed by two proteins expressed by the Env gene This viral envelope binds to the host cell s receptor and is what gains the virus entry into the cell 150 With mRNA vaccines mRNA or messenger RNA contains the instructions for how to make the spike protein The mRNA is put into lipid based nanoparticles for drug delivery This was a key breakthrough in optimizing the efficiency and efficacy of in vivo delivery 151 152 When the vaccine is injected the mRNA enters cells and joins up with a ribosome The ribosome then translates the mRNA instructions into the spike protein The immune system detects the presence of the spike protein and B cells a type of white blood cell begin to develop antibodies Should the actual virus later enter the system the external spike protein will be recognized by memory B cells whose function is to memorize the characteristics of the original antigen Memory B cells then produce the antibodies hopefully destroying the virus before it can bind to another cell and repeat the HIV life cycle 153 SARS CoV 2 and HIV 1 have similarities notably both are RNA viruses but there are important differences As a retrovirus HIV 1 can insert a copy of its RNA genome into the host s DNA making total eradication more difficult 154 The virus is also highly mutable making it a challenge for the adaptive immune system to develop a response As a chronic infection HIV 1 and the adaptive immune system undergo reciprocal selective pressures leading to the evolutionary arms race of coevolution 155 Broadly neutralizing HIV 1 antibodies or bnAbs have been shown to attach to the Env spike protein envelope regardless of the specific HIV mutations 156 157 158 This bodes well for vaccine development Complicating matters though naive B cells mature B cells not yet exposed to any antigen and are the progenitors of bnAbs are rare Further the mutation events needed to turn these B cells into bnAbs are also rare 159 160 Because of this there is a growing consensus that an effective HIV vaccine will need to create not only humoral antibody mediated immunity but a T cell mediated immunity 161 159 mRNA vaccines have advantages over traditional vaccines which may help deal with some of the challenges presented by the HIV virus The mRNA in the vaccine only codes for the protein spike not the whole virus so the possibility of reverse transcription where the virus copies its genetic material into the host s genome is not present Another advantage when compared to traditional vaccines is the speed of development mRNA vaccines take months not years which means a multipart sequential vaccine regime is possible citation needed Attempts to elicit an immune response that triggers broadly neutralizing antibodies bnAbs with a single vaccine dose have been unsuccessful A multipart sequential mRNA vaccine regime however might guide the immune response in the right direction The first shot triggers an immune response for the correct naive B cells Later vaccinations encourage the development of these cells further eventually turning them into memory b cells and later into plasma cells which can secrete the broadly neutralizing antibodies In essence the sequential immunization approach represents an attempt to mimic Env evolution that would occur with natural infection In contrast to traditional prime boost strategies in which the same immunogen is used repeatedly for vaccination the sequential immunization approach relies on a series of different immunogens with the goal of eventually inducing bnAb s 159 A Phase 1 clinical trial by Scripps Research and the International AIDS Vaccine Initiative of an mRNA vaccine showed that 97 percent of participants had the desired initial priming immune response of naive b cells 160 This is a positive result for developing the first shot in a vaccine sequence Moderna is partnering with Scripps and the International AIDS Vaccine Initiative for a follow up phase 1 clinical trial of an HIV mRNA vaccine mRNA 1644 starting later in 2021 162 Drug advertisements EditDirect to consumer and other advertisements for HIV drugs in the past were criticized for their use of healthy glamorous models rather than typical people with HIV AIDS Usually these people will present with debilitating conditions or illnesses as a result of HIV AIDS In contrast by featuring people in unrealistically strenuous activities such as mountain climbing 163 this proved to be offensive and insensitive to the suffering of people who are HIV positive The US FDA reprimanded multiple pharmaceutical manufacturers for publishing such adverts in 2001 as the misleading advertisements harmed consumers by implying unproven benefits and failing to disclose important information about the drugs 164 Overall some drug companies chose not to present their drugs in a realistic way which consequently harmed the general public s ideas citation needed suggesting that HIV would not affect you as much as suggested This led to people not wanting to get tested citation needed for fear of being HIV positive because at the time in the 80s and 90s particularly having contracted HIV was seen as a death sentence as there was no known cure An example of such a case is Freddie Mercury citation needed who died in 1991 aged 45 of AIDS related pneumonia Beyond medical management EditThe preamble to the World Health Organization s Constitution defines health as a state of complete physical mental and social well being and not merely the absence of disease or infirmity 165 Those living with HIV today are met with other challenges that go beyond the singular goal of lowering their viral load A 2009 meta analysis studying the correlates of HIV stigma found that individuals living with higher stigma burden were more likely to have poorer physical and mental health 9 Insufficient social support and delayed diagnosis due to decreased frequency of HIV testing and knowledge of risk reduction were cited as some of the reasons 9 166 8 167 168 People living with HIV PLHIV have lower health related quality of life HRQoL scores than do the general population 167 166 The stigma of having HIV is often compounded with the stigma of identifying with the LGBTQ community or the stigma of being an injecting drug user IDU even though heterosexual sexual transmission accounts for 85 of all HIV 1 infections worldwide 169 103 AIDS has been cited as the most heavily stigmatized medical condition among infectious diseases 168 Part of the consequence of this stigma toward PLHIV is the belief that they are seen as responsible for their status and less deserving of treatment 169 9 A 2016 study sharing the WHO s definition of health critiques its 90 90 90 target goal which is part of a larger strategy that aims to eliminate the AIDS epidemic as a public health threat by 2030 by arguing that it does not go far enough in ensuring the holistic health of PLHIV 8 The study suggests that maintenance of HIV and AIDS should go beyond the suppression of viral load and the prevention of opportunistic infection It proposes adding a fourth 90 addressing a new quality of life target that would focus specifically on increasing the quality of life for those that are able to suppress their viral load to undetectable levels along with new metrics to track the progress toward that target 8 This study serves as an example of the shifting paradigm in the dynamics of the health care system from being heavily disease oriented to more human centered Though questions remain of what exactly a more human centered method of treatment looks like in practice it generally aims to ask what kind of support other than medical support PLHIV need to cope with and eliminate HIV related stigmas 9 8 Campaigns and marketing aimed at educating the general public in order to reduce any misplaced fears of HIV contraction is one example 9 Also encouraged is the capacity building and guided development of PLHIV into more leadership roles with the goal of having a greater representation of this population in decision making positions 9 Structural legal intervention has also been proposed specifically referring to legal interventions to put in place protections against discrimination and improve access to employment opportunities 9 On the side of the practitioner greater competence for the experience of people living with HIV is encouraged alongside the promotion of an environment of nonjudgment and confidentiality 9 Psychosocial group interventions such as psychotherapy relaxation group support and education may have some beneficial effects on depression in HIV positive people 170 Food insecurity EditThe successful treatment and management of HIV AIDS is affected by a plethora of factors which ranges from successfully taking prescribed medications preventing opportunistic infection and food access etc Food insecurity is a condition in which households lack access to adequate food because of limited money or other resources Food insecurity is a global issue that have affect billions of people yearly including those living in developed countries citation needed Food insecurity is a major public health disparity in the United States of America which significantly affects minority groups people living at or below the poverty line and those who are living with one or more morbidity As of December 31 2017 there were approximately 126 742 people living with HIV AIDS PLWHA in NYC of whom 87 6 can be described as living with some level of poverty and food insecurity as reported by the NYC Department of Health March 31 2019 171 Having access to a consistent food supply that is safe and healthy is an important part in the treatment and management of HIV AIDS PLWHA are also greatly affected by food inequities and food deserts which causes them to be food insecure Food insecurity which can cause malnutrition can also negatively impact HIV treatment and recovery from opportunistic infections Similarly PLWHA require additional calories and nutritionally support that require foods free from contamination to prevent further immunocompromising Food insecurity can further exacerbate the progression of HIV AIDS and can prevent PLWHA from consistently following their prescribed regimen which will lead to poor outcomes citation needed It is imperative that these food insecurity among PLWHA are addressed and rectified to reduce this health inequity 172 circular reference It is important to recognized that socioeconomic status access to medical care geographic location public policy race and ethnicity all play a pivotal role in the treatment and management of HIV AIDS The lack of sufficient and constant income does limit the options for food treatment and medications The same can be inferred for those who are among the oppressed groups in society who are marginalized and may be less inclined or encouraged to seek care and assistance Endeavors to address food insecurity should be included in HIV treatment programs and may help improve health outcomes if it also focuses on health equity among the diagnosed as much as it focuses on medications Access to consistently safe and nutritious foods is one of the most important facets in ensuring PLWHA are being provided the best possible care By altering the narratives for HIV treatment so that more support can be garnered to reduce food insecurity and other health disparities mortality rates will decrease for people living with HIV AIDS citation needed See also EditAntiviral drug AV HALT Discovery and development of HIV protease inhibitors Discovery and development of non nucleoside reverse transcriptase inhibitors Discovery and development of nucleoside and nucleotide reverse transcriptase inhibitors HIV capsid inhibitionReferences Edit Arachchige AS 2021 A universal CAR NK cell approach for HIV eradication AIMS Allergy and Immunology 5 3 192 194 doi 10 3934 Allergy 2021015 a b Moore RD Chaisson RE October 1999 Natural history of HIV infection in the era of combination antiretroviral therapy AIDS 13 14 1933 42 doi 10 1097 00002030 199910010 00017 PMID 10513653 a b Eisinger RW Dieffenbach CW Fauci AS February 2019 HIV Viral Load and Transmissibility of HIV Infection Undetectable Equals Untransmittable JAMA 321 5 451 452 doi 10 1001 jama 2018 21167 PMID 30629090 S2CID 58599661 Fauci AS Folkers GK July 2012 Toward an AIDS free generation JAMA 308 4 343 4 doi 10 1001 jama 2012 8142 PMID 22820783 Deeks SG Lewin SR Havlir DV November 2013 The end of AIDS HIV infection as a chronic disease Lancet 382 9903 1525 33 doi 10 1016 S0140 6736 13 61809 7 PMC 4058441 PMID 24152939 a b c Guidelines HIV World Health Organization Archived from the original on March 26 2005 Retrieved 2015 10 27 a b c d e f g h i j k l m n o Guidelines for the Use of Antiretroviral Agents in HIV 1 Infected Adults and Adolescents PDF US Department of Health and Human Services 2015 04 08 a href Template Cite journal html title Template Cite journal cite journal a Cite journal requires journal help a b c d e Lazarus JV Safreed Harmon K Barton SE Costagliola D Dedes N Del Amo Valero J et al June 2016 Beyond viral suppression of HIV the new quality of life frontier BMC Medicine 14 1 94 doi 10 1186 s12916 016 0640 4 PMC 4916540 PMID 27334606 a b c d e f g h i Logie C Gadalla TM June 2009 Meta analysis of health and demographic correlates of stigma towards people living with HIV AIDS Care 21 6 742 53 doi 10 1080 09540120802511877 PMID 19806490 S2CID 29881807 Lieberman Blum SS Fung HB Bandres JC July 2008 Maraviroc a CCR5 receptor antagonist for the treatment of HIV 1 infection Clinical Therapeutics 30 7 1228 50 doi 10 1016 S0149 2918 08 80048 3 PMID 18691983 Bai Y Xue H Wang K Cai L Qiu J Bi S et al February 2013 Covalent fusion inhibitors targeting HIV 1 gp41 deep pocket Amino Acids 44 2 701 13 doi 10 1007 s00726 012 1394 8 PMID 22961335 S2CID 18521851 a b Das K Arnold E April 2013 HIV 1 reverse transcriptase and antiviral drug resistance Part 1 Current Opinion in Virology 3 2 111 8 doi 10 1016 j coviro 2013 03 012 PMC 4097814 PMID 23602471 a b Geretti ed 2006 9 Antiretroviral Resistance in Clinical Practice Mediscript ISBN 978 0 955 16690 7 Metifiot M Marchand C Pommier Y 2013 HIV integrase inhibitors 20 year landmark and challenges Antiviral Agents Advances in Pharmacology Vol 67 pp 75 105 doi 10 1016 B978 0 12 405880 4 00003 2 ISBN 9780124058804 PMC 7569752 PMID 23885999 a b Wensing AM van Maarseveen NM Nijhuis M January 2010 Fifteen years of HIV Protease Inhibitors raising the barrier to resistance Antiviral Research 85 1 59 74 doi 10 1016 j antiviral 2009 10 003 PMID 19853627 Myriad Genetics suspends its HIV maturation inhibitor program AIDSmeds 8 June 2012 Archived from the original on 8 September 2015 Retrieved 27 June 2012 Perelson AS Neumann AU Markowitz M Leonard JM Ho DD March 1996 HIV 1 dynamics in vivo virion clearance rate infected cell life span and viral generation time Science 271 5255 1582 6 Bibcode 1996Sci 271 1582P CiteSeerX 10 1 1 34 7762 doi 10 1126 science 271 5255 1582 PMID 8599114 S2CID 13638059 a b Smyth RP Davenport MP Mak J November 2012 The origin of genetic diversity in HIV 1 Virus Research 169 2 415 29 doi 10 1016 j virusres 2012 06 015 PMID 22728444 Schmit JC Cogniaux J Hermans P Van Vaeck C Sprecher S Van Remoortel B et al November 1996 Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain The Journal of Infectious Diseases 174 5 962 8 doi 10 1093 infdis 174 5 962 PMID 8896496 Henkel J July August 1999 Attacking AIDS with a cocktail therapy FDA Consumer Food and Drug Administration US Dept of Health and Human Services Archived from the original on 2009 01 14 a b Bangsberg DR Kroetz DL Deeks SG May 2007 Adherence resistance relationships to combination HIV antiretroviral therapy Current HIV AIDS Reports 4 2 65 72 doi 10 1007 s11904 007 0010 0 PMID 17547827 S2CID 45429207 Fixed dose combinations AIDSmap March 2011 Retrieved 2014 04 09 Bangalore S Kamalakkannan G Parkar S Messerli FH August 2007 Fixed dose combinations improve medication compliance a meta analysis The American Journal of Medicine 120 8 713 9 doi 10 1016 j amjmed 2006 08 033 PMID 17679131 Onwumeh J Okwundu CI Kredo T May 2017 Interleukin 2 as an adjunct to antiretroviral therapy for HIV positive adults The Cochrane Database of Systematic Reviews 2017 5 CD009818 doi 10 1002 14651858 CD009818 pub2 PMC 5458151 PMID 28542796 Darbyshire J 1995 Perspectives in drug therapy of HIV infection Drugs 49 Suppl 1 Supplement 1 1 3 discussion 38 40 doi 10 2165 00003495 199500491 00003 PMID 7614897 S2CID 754662 a b Gulick RM Mellors JW Havlir D Eron JJ Gonzalez C McMahon D Richman DD Valentine FT Jonas L Meibohm A Emini EA Chodakewitz JA September 1997 Treatment with indinavir zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy The New England Journal of Medicine 337 11 734 9 doi 10 1056 NEJM199709113371102 PMID 9287228 Ho DD August 1995 Time to hit HIV early and hard The New England Journal of Medicine 333 7 450 1 doi 10 1056 NEJM199508173330710 PMID 7616996 Harrington M Carpenter CC June 2000 Hit HIV 1 hard but only when necessary Lancet 355 9221 2147 52 doi 10 1016 S0140 6736 00 02388 6 PMID 10902643 S2CID 22747572 Sonenklar C 2011 Chapter 6 Treatment for HIV and AIDS AIDS USA Today Health Reports Diseases and Disorders Minneapolis MN Twenty First Century Books pp 90 101 ISBN 9780822585817 a b Kitahata MM Gange SJ Abraham AG Merriman B Saag MS Justice AC et al April 2009 Effect of early versus deferred antiretroviral therapy for HIV on survival The New England Journal of Medicine 360 18 1815 26 doi 10 1056 NEJMoa0807252 PMC 2854555 PMID 19339714 Lundgren JD Babiker AG Gordin F Emery S Grund B Sharma S et al August 2015 Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The New England Journal of Medicine 373 9 795 807 doi 10 1056 NEJMoa1506816 PMC 4569751 PMID 26192873 Danel C Moh R Gabillard D Badje A Le Carrou J Ouassa T et al August 2015 A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa The New England Journal of Medicine 373 9 808 22 doi 10 1056 NEJMoa1507198 hdl 10044 1 41218 PMID 26193126 Kelley CF Kitchen CM Hunt PW Rodriguez B Hecht FM Kitahata M et al March 2009 Incomplete peripheral CD4 cell count restoration in HIV infected patients receiving long term antiretroviral treatment Clinical Infectious Diseases 48 6 787 94 doi 10 1086 597093 PMC 2720023 PMID 19193107 Monforte A Abrams D Pradier C Weber R Reiss P Bonnet F et al October 2008 HIV induced immunodeficiency and mortality from AIDS defining and non AIDS defining malignancies AIDS 22 16 2143 53 doi 10 1097 QAD 0b013e3283112b77 PMC 2715844 PMID 18832878 a b c d First long acting injectable antiretroviral therapy for HIV recommended approval European Medicines Agency EMA Press release 16 October 2020 Retrieved 16 October 2020 Text was copied from this source which is c European Medicines Agency Reproduction is authorized provided the source is acknowledged Graham SM Holte SE Peshu NM Richardson BA Panteleeff DD Jaoko WG et al February 2007 Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV 1 shedding AIDS 21 4 501 7 doi 10 1097 QAD 0b013e32801424bd PMID 17301569 S2CID 21335467 Vernazza PL Troiani L Flepp MJ Cone RW Schock J Roth F et al January 2000 Potent antiretroviral treatment of HIV infection results in suppression of the seminal shedding of HIV The Swiss HIV Cohort Study AIDS 14 2 117 21 CiteSeerX 10 1 1 567 3563 doi 10 1097 00002030 200001280 00006 PMID 10708281 S2CID 3035239 Cohen MS Chen YQ McCauley M Gamble T Hosseinipour MC Kumarasamy N et al August 2011 Prevention of HIV 1 infection with early antiretroviral therapy The New England Journal of Medicine 365 6 493 505 doi 10 1056 NEJMoa1105243 PMC 3200068 PMID 21767103 Cohen MS Smith MK Muessig KE Hallett TB Powers KA Kashuba AD November 2013 Antiretroviral treatment of HIV 1 prevents transmission of HIV 1 where do we go from here Lancet 382 9903 1515 24 doi 10 1016 S0140 6736 13 61998 4 PMC 3880570 PMID 24152938 Cohen J December 2011 Breakthrough of the year HIV treatment as prevention Science 334 6063 1628 Bibcode 2011Sci 334 1628C doi 10 1126 science 334 6063 1628 PMID 22194547 a b c Consensus statement Risk of Sexual Transmission of HIV from a Person Living with HIV who has an Undetectable Viral Load Prevention Access Campaign 21 July 2016 Retrieved 2 April 2019 Note When the statement and list of endorsements was retrieved it had last been updated on 23 August 2018 and included over 850 organizations from nearly 100 countries a b c Rodger AJ Cambiano V Bruun T Vernazza P Collins S van Lunzen J et al July 2016 Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV Positive Partner Is Using Suppressive Antiretroviral Therapy JAMA 316 2 171 81 doi 10 1001 jama 2016 5148 PMID 27404185 PARTNER Partners of People on ART A New Evaluation of the Risks a b c d e f Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection lt WHO June 30 2013 p 38 ISBN 978 92 4 150572 7 a b El Sadr WM Lundgren J Neaton JD Gordin F Abrams D Arduino RC Babiker A Burman W Clumeck N Cohen CJ Cohn D Cooper D Darbyshire J Emery S Fatkenheuer G Gazzard B Grund B Hoy J Klingman K Losso M Markowitz N Neuhaus J Phillips A Rappoport C November 2006 CD4 count guided interruption of antiretroviral treatment PDF The New England Journal of Medicine 355 22 2283 96 doi 10 1056 NEJMoa062360 PMID 17135583 S2CID 32501272 a b Silverberg MJ Neuhaus J Bower M Gey D Hatzakis A Henry K et al September 2007 Risk of cancers during interrupted antiretroviral therapy in the SMART study AIDS 21 14 1957 63 doi 10 1097 QAD 0b013e3282ed6338 PMID 17721103 S2CID 16090838 Gunthard HF Aberg JA Eron JJ Hoy JF Telenti A Benson CA et al 2014 07 23 Antiretroviral treatment of adult HIV infection 2014 recommendations of the International Antiviral Society USA Panel JAMA 312 4 410 25 doi 10 1001 jama 2014 8722 PMID 25038359 EACS Guidelines 8 0 www eacsociety org Retrieved 2016 01 14 Cane P Chrystie I Dunn D Evans B Geretti AM Green H et al December 2005 Time trends in primary resistance to HIV drugs in the United Kingdom multicentre observational study BMJ 331 7529 1368 doi 10 1136 bmj 38665 534595 55 PMC 1309643 PMID 16299012 Novak RM Chen L MacArthur RD Baxter JD Huppler Hullsiek K Peng G et al February 2005 Prevalence of antiretroviral drug resistance mutations in chronically HIV infected treatment naive patients implications for routine resistance screening before initiation of antiretroviral therapy Clinical Infectious Diseases 40 3 468 74 doi 10 1086 427212 PMID 15668873 Descamps D Assoumou L Chaix ML Chaillon A Pakianather S de Rougemont A et al November 2013 National sentinel surveillance of transmitted drug resistance in antiretroviral naive chronically HIV infected patients in France over a decade 2001 2011 The Journal of Antimicrobial Chemotherapy 68 11 2626 31 doi 10 1093 jac dkt238 PMID 23798669 Sungkanuparph S Pasomsub E Chantratita W Jan Feb 2014 Surveillance of transmitted HIV drug resistance in antiretroviral naive patients aged less than 25 years in Bangkok Thailand Journal of the International Association of Providers of AIDS Care 13 1 12 4 doi 10 1177 2325957413488200 PMID 23708678 Gagliardo C Brozovich A Birnbaum J Radix A Foca M Nelson J et al March 2014 A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral naive adolescents and young adults with HIV in New York City Clinical Infectious Diseases 58 6 865 72 doi 10 1093 cid ciu003 PMC 3988426 PMID 24429431 Perez L Kouri V Aleman Y Abrahantes Y Correa C Aragones C et al June 2013 Antiretroviral drug resistance in HIV 1 therapy naive patients in Cuba Infection Genetics and Evolution 16 144 50 doi 10 1016 j meegid 2013 02 002 PMID 23416260 Mbuagbaw L Mursleen S Irlam JH Spaulding AB Rutherford GW Siegfried N et al Cochrane Infectious Diseases Group December 2016 Efavirenz or nevirapine in three drug combination therapy with two nucleoside or nucleotide reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral naive individuals The Cochrane Database of Systematic Reviews 2016 12 CD004246 doi 10 1002 14651858 CD004246 pub4 PMC 5450880 PMID 27943261 a b c d Antiretroviral Therapy for Human Immunodeficiency Virus Infection Mandell Douglas and Bennett s Principles and Practice of Infectious Diseases 7th ed Churchill Livingstone 2009 ISBN 978 0 443 06839 3 Lepist EI Phan TK Roy A Tong L Maclennan K Murray B Ray AS October 2012 Cobicistat boosts the intestinal absorption of transport substrates including HIV protease inhibitors and GS 7340 in vitro Antimicrobial Agents and Chemotherapy 56 10 5409 13 doi 10 1128 AAC 01089 12 PMC 3457391 PMID 22850510 Fidler S Porter K Ewings F Frater J Ramjee G Cooper D et al January 2013 Short course antiretroviral therapy in primary HIV infection The New England Journal of Medicine 368 3 207 17 doi 10 1056 NEJMoa1110039 PMC 4131004 PMID 23323897 Hollingsworth TD Anderson RM Fraser C September 2008 HIV 1 transmission by stage of infection The Journal of Infectious Diseases 198 5 687 93 doi 10 1086 590501 PMID 18662132 Newell ML Coovadia H Cortina Borja M Rollins N Gaillard P Dabis F October 8 2004 Mortality of infected and uninfected infants born to HIV infected mothers in Africa a pooled analysis Lancet 364 9441 1236 43 doi 10 1016 S0140 6736 04 17140 7 PMID 15464184 S2CID 24511465 a b Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection PDF US Department of Health and Human Services February 12 2014 pp 50 61 Retrieved April 11 2014 Musiime V Ssali F Kayiwa J Namala W Kizito H Kityo C Mugyenyi P October 2009 Response to nonnucleoside reverse transcriptase inhibitor based therapy in HIV infected children with perinatal exposure to single dose nevirapine AIDS Research and Human Retroviruses 25 10 989 96 doi 10 1089 aid 2009 0054 PMID 19778270 Violari A Lindsey JC Hughes MD Mujuru HA Barlow Mosha L Kamthunzi P et al June 2012 Nevirapine versus ritonavir boosted lopinavir for HIV infected children The New England Journal of Medicine 366 25 2380 9 doi 10 1056 NEJMoa1113249 PMC 3443859 PMID 22716976 Adetokunboh OO Schoonees A Balogun TA Wiysonge CS October 2015 Efficacy and safety of abacavir containing combination antiretroviral therapy as first line treatment of HIV infected children and adolescents a systematic review and meta analysis BMC Infectious Diseases 15 1 469 doi 10 1186 s12879 015 1183 6 PMC 4623925 PMID 26502899 Garcia PM Kalish LA Pitt J Minkoff H Quinn TC Burchett SK Kornegay J Jackson B Moye J Hanson C Zorrilla C Lew JF August 1999 Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission Women and Infants Transmission Study Group The New England Journal of Medicine 341 6 394 402 doi 10 1056 NEJM199908053410602 PMID 10432324 a b European Collaborative Study February 2005 Mother to child transmission of HIV infection in the era of highly active antiretroviral therapy Clinical Infectious Diseases 40 3 458 65 doi 10 1086 427287 PMID 15668871 a b Recommendations for Use of Antiretroviral Drugs in Pregnant HIV 1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States PDF US DHHS March 28 2014 Retrieved 2014 04 11 Rousseau CM Nduati RW Richardson BA Steele MS John Stewart GC Mbori Ngacha DA et al March 2003 Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease The Journal of Infectious Diseases 187 5 741 7 doi 10 1086 374273 PMC 3384731 PMID 12599047 May MT Gompels M Delpech V Porter K Orkin C Kegg S et al May 2014 Impact on life expectancy of HIV 1 positive individuals of CD4 cell count and viral load response to antiretroviral therapy AIDS 28 8 1193 202 doi 10 1097 QAD 0000000000000243 PMC 4004637 PMID 24556869 Nakagawa F May M Phillips A February 2013 Life expectancy living with HIV recent estimates and future implications Current Opinion in Infectious Diseases 26 1 17 25 doi 10 1097 QCO 0b013e32835ba6b1 PMID 23221765 S2CID 7554571 Silverberg MJ Leyden W Horberg MA DeLorenze GN Klein D Quesenberry CP April 2007 Older age and the response to and tolerability of antiretroviral therapy Archives of Internal Medicine 167 7 684 91 doi 10 1001 archinte 167 7 684 PMID 17420427 Althoff KN Justice AC Gange SJ Deeks SG Saag MS Silverberg MJ Gill MJ Lau B Napravnik S Tedaldi E Klein MB Gebo KA October 2010 Virologic and immunologic response to HAART by age and regimen class AIDS 24 16 2469 79 doi 10 1097 QAD 0b013e32833e6d14 PMC 3136814 PMID 20829678 a b Greene M Justice AC Lampiris HW Valcour V April 2013 Management of human immunodeficiency virus infection in advanced age JAMA 309 13 1397 405 doi 10 1001 jama 2013 2963 PMC 3684249 PMID 23549585 a b Eshun Wilson I Siegfried N Akena DH Stein DJ Obuku EA Joska JA January 2018 Antidepressants for depression in adults with HIV infection The Cochrane Database of Systematic Reviews 1 1 CD008525 doi 10 1002 14651858 CD008525 pub3 PMC 6491182 PMID 29355886 Gardner EM Burman WJ Steiner JF Anderson PL Bangsberg DR June 2009 Antiretroviral medication adherence and the development of class specific antiretroviral resistance AIDS 23 9 1035 46 doi 10 1097 QAD 0b013e32832ba8ec PMC 2704206 PMID 19381075 Global Price Reporting Mechanism for HIV tuberculosis and malaria World Health Organization Archived from the original on May 20 2006 Retrieved 2014 04 11 Antiretroviral Drug Prices Avert Retrieved 2014 04 12 New one pill 10 per month anti retroviral AIDS treatment debuts in South Africa The Raw Story Agence France Presse 2013 Walensky RP Ross EL Kumarasamy N Wood R Noubary F Paltiel AD et al October 2013 Cost effectiveness of HIV treatment as prevention in serodiscordant couples The New England Journal of Medicine 369 18 1715 25 doi 10 1056 NEJMsa1214720 PMC 3913536 PMID 24171517 Horn T August 28 2012 Activists Protest Stribild s 28 500 Price Tag AIDSMeds Retrieved 2014 04 11 Stribild GoodRx Retrieved 2014 04 11 Beardsley T July 1998 Coping with HIV s ethical dilemmas Scientific American 279 1 106 7 Bibcode 1998SciAm 279a 106B doi 10 1038 scientificamerican0798 106 PMID 9648307 a b c Thompson MA Aberg JA Hoy JF Telenti A Benson C Cahn P et al July 2012 Antiretroviral treatment of adult HIV infection 2012 recommendations of the International Antiviral Society USA panel JAMA 308 4 387 402 doi 10 1001 jama 2012 7961 PMID 22820792 S2CID 205038135 Murray JS Elashoff MR Iacono Connors LC Cvetkovich TA Struble KA May 1999 The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs AIDS 13 7 797 804 doi 10 1097 00002030 199905070 00008 PMID 10357378 Swiss National AIDS Commission 15 October 2016 The Swiss statement HIV i Base Retrieved 2 April 2019 The Lancet Hiv November 2017 U U taking off in 2017 Editorial The Lancet HIV 4 11 e475 doi 10 1016 S2352 3018 17 30183 2 PMID 29096785 Can t Pass It On Terrence Higgins Trust 2019 Archived from the original on 7 April 2019 Retrieved 2 April 2019 a b c d Hoffman H 10 January 2019 The science is clear with HIV undetectable equals untransmittable Press release National Institutes of Health National Institute of Allergy and Infectious Diseases Retrieved 3 May 2019 NIAID Director Anthony S Fauci M D and colleagues summarize results from large clinical trials and cohort studies validating U U The landmark NIH funded HPTN 052 clinical trial showed that no linked HIV transmissions occurred among HIV serodifferent heterosexual couples when the partner living with HIV had a durably suppressed viral load Subsequently the PARTNER and Opposites Attract studies confirmed these findings and extended them to male male couples The success of U U as an HIV prevention method depends on achieving and maintaining an undetectable viral load by taking ART daily as prescribed Bavinton BR Pinto AN Phanuphak N Grinsztejn B Prestage GP Zablotska Manos IB et al August 2018 Viral suppression and HIV transmission in serodiscordant male couples an international prospective observational cohort study The Lancet HIV 5 8 e438 e447 doi 10 1016 S2352 3018 18 30132 2 PMID 30025681 S2CID 51702998 a b c Rodger AJ Cambiano V Bruun T Vernazza P Collins S Degen O et al May 2019 Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV positive partner taking suppressive antiretroviral therapy PARTNER final results of a multicentre prospective observational study Lancet 393 10189 2428 2438 doi 10 1016 S0140 6736 19 30418 0 PMC 6584382 PMID 31056293 Rodger A for the PARTNER study group July 2018 Risk of HIV transmission through condomless sex in MSM couples with suppressive ART The PARTNER2 Study extended results in gay men AIDS2018 22nd International AIDS Conference Amsterdam the Netherlands Retrieved 2 April 2019 Cohen MS Chen YQ McCauley M Gamble T Hosseinipour MC Kumarasamy N et al September 2016 Antiretroviral Therapy for the Prevention of HIV 1 Transmission The New England Journal of Medicine 375 9 830 9 doi 10 1056 NEJMoa1600693 PMC 5049503 PMID 27424812 Hodson M 17 November 2017 U U Talking to patients about transmission risk PDF British HIV Association Autumn Conference 2017 Retrieved 3 May 2019 abstract for presentation on behalf of NAM AIDSmap Boseley S Devlin H 3 May 2019 End to AIDS in sight as huge study finds drugs stop HIV transmission The Guardian Retrieved 3 May 2019 Hughes MD Stein DS Gundacker HM Valentine FT Phair JP Volberding PA January 1994 Within subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection implications for patient monitoring The Journal of Infectious Diseases 169 1 28 36 doi 10 1093 infdis 169 1 28 PMID 7903975 Lok JJ Bosch RJ Benson CA Collier AC Robbins GK Shafer RW Hughes MD July 2010 Long term increase in CD4 T cell counts during combination antiretroviral therapy for HIV 1 infection AIDS 24 12 1867 76 doi 10 1097 QAD 0b013e32833adbcf PMC 3018341 PMID 20467286 Gazzola L Tincati C Bellistri GM Monforte A Marchetti G February 2009 The absence of CD4 T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy clinical risk immunological gaps and therapeutic options Clinical Infectious Diseases 48 3 328 37 doi 10 1086 695852 PMID 19123868 Kloverpris HN Kazer SW Mjosberg J Mabuka JM Wellmann A Ndhlovu Z et al February 2016 Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV 1 Infection in the Absence of Viral Suppression Immunity 44 2 391 405 doi 10 1016 j immuni 2016 01 006 PMC 6836297 PMID 26850658 Sonnenberg GF Monticelli LA Alenghat T Fung TC Hutnick NA Kunisawa J et al June 2012 Innate lymphoid cells promote anatomical containment of lymphoid resident commensal bacteria Science 336 6086 1321 5 Bibcode 2012Sci 336 1321S doi 10 1126 science 1222551 PMC 3659421 PMID 22674331 Chung CY Alden SL Funderburg NT Fu P Levine AD June 2014 Progressive proximal to distal reduction in expression of the tight junction complex in colonic epithelium of virally suppressed HIV individuals PLOS Pathogens 10 6 e1004198 doi 10 1371 journal ppat 1004198 PMC 4072797 PMID 24968145 Stanford University HIV Drug Resistance Database Retrieved 2014 04 13 Aves T Tambe J Siemieniuk RA Mbuagbaw L et al Cochrane Infectious Diseases Group November 2018 Antiretroviral resistance testing in HIV positive people The Cochrane Database of Systematic Reviews 11 CD006495 doi 10 1002 14651858 CD006495 pub5 PMC 6517236 PMID 30411789 Miller V Cozzi Lepri A Hertogs K Gute P Larder B Bloor S et al March 2000 HIV drug susceptibility and treatment response to mega HAART regimen in patients from the Frankfurt HIV cohort Antiviral Therapy 5 1 49 55 doi 10 1177 135965350000500113 PMID 10846593 S2CID 33402816 a b c Simon V Ho DD Abdool Karim Q August 2006 HIV AIDS epidemiology pathogenesis prevention and treatment Lancet 368 9534 489 504 doi 10 1016 S0140 6736 06 69157 5 PMC 2913538 PMID 16890836 Johnson AA Ray AS Hanes J Suo Z Colacino JM Anderson KS Johnson KA November 2001 Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase The Journal of Biological Chemistry 276 44 40847 57 doi 10 1074 jbc M106743200 PMID 11526116 Birkus G Hitchcock MJ Cihlar T March 2002 Assessment of mitochondrial toxicity in human cells treated with tenofovir comparison with other nucleoside reverse transcriptase inhibitors Antimicrobial Agents and Chemotherapy 46 3 716 23 doi 10 1128 aac 46 3 716 723 2002 PMC 127499 PMID 11850253 Hulgan T Robbins GK Kalams SA Samuels DC Grady B Shafer R et al 27 August 2012 T cell activation markers and African mitochondrial DNA haplogroups among non Hispanic black participants in AIDS clinical trials group study 384 PLOS ONE 7 8 e43803 Bibcode 2012PLoSO 743803H doi 10 1371 journal pone 0043803 PMC 3433792 PMID 22970105 Guzman Fulgencio M Berenguer J Micheloud D Fernandez Rodriguez A Garcia Alvarez M Jimenez Sousa MA et al October 2013 European mitochondrial haplogroups are associated with CD4 T cell recovery in HIV infected patients on combination antiretroviral therapy The Journal of Antimicrobial Chemotherapy 68 10 2349 2357 doi 10 1093 jac dkt206 PMID 23749950 Hart AB Samuels DC Hulgan T October 2013 The other genome a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy AIDS Reviews 15 4 213 220 PMC 4001077 PMID 24322381 Mitochondrial haplogroup H is related to CD4 T cell recovery in HIV infected patients starting combination antiretroviral therapy Boelsterli UA Lim PL April 2007 Mitochondrial abnormalities a link to idiosyncratic drug hepatotoxicity Toxicology and Applied Pharmacology 220 1 92 107 doi 10 1016 j taap 2006 12 013 PMID 17275868 Usach I Melis V Peris JE September 2013 Non nucleoside reverse transcriptase inhibitors a review on pharmacokinetics pharmacodynamics safety and tolerability Journal of the International AIDS Society 16 1 18567 doi 10 7448 ias 16 1 18567 PMC 3764307 PMID 24008177 Walmsley S June 2007 Protease inhibitor based regimens for HIV therapy safety and efficacy Journal of Acquired Immune Deficiency Syndromes 45 Suppl 1 Supplement 1 S5 13 quiz S28 31 doi 10 1097 QAI 0b013e3180600709 PMID 17525691 S2CID 3113311 Lee FJ Carr A September 2012 Tolerability of HIV integrase inhibitors Current Opinion in HIV and AIDS 7 5 422 8 doi 10 1097 COH 0b013e328356682a PMID 22886031 S2CID 29497910 Bell DM May 1997 Occupational risk of human immunodeficiency virus infection in healthcare workers an overview The American Journal of Medicine 102 5B 9 15 doi 10 1016 s0002 9343 97 89441 7 PMID 9845490 Ippolito G Puro V De Carli G June 1993 The risk of occupational human immunodeficiency virus infection in health care workers Italian Multicenter Study The Italian Study Group on Occupational Risk of HIV infection Archives of Internal Medicine 153 12 1451 8 doi 10 1001 archinte 1993 00410120035005 PMID 8512436 a b c Kuhar DT Henderson DK Struble KA Heneine W Thomas V Cheever LW Gomaa A Panlilio AL September 2013 Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis Infection Control and Hospital Epidemiology 34 9 875 92 doi 10 1086 672271 JSTOR 672271 PMID 23917901 S2CID 17032413 Cardo DM Culver DH Ciesielski CA Srivastava PU Marcus R Abiteboul D et al November 1997 A case control study of HIV seroconversion in health care workers after percutaneous exposure Centers for Disease Control and Prevention Needlestick Surveillance Group The New England Journal of Medicine 337 21 1485 90 doi 10 1056 NEJM199711203372101 PMID 9366579 Glynn JR Buve A Carael M Kahindo M Macauley IB Musonda RM Jungmann E Tembo F Zekeng L December 2000 Decreased fertility among HIV 1 infected women attending antenatal clinics in three African cities Journal of Acquired Immune Deficiency Syndromes 25 4 345 52 doi 10 1097 00126334 200012010 00008 PMID 11114835 S2CID 22980353 a b Savasi V Mandia L Laoreti A Cetin I 2012 Reproductive assistance in HIV serodiscordant couples Human Reproduction Update 19 2 136 50 doi 10 1093 humupd dms046 PMID 23146867 Centers for Disease Control CDC April 1990 HIV 1 infection and artificial insemination with processed semen MMWR Morbidity and Mortality Weekly Report 39 15 249 255 6 PMID 2109169 Savasi V Ferrazzi E Lanzani C Oneta M Parrilla B Persico T March 2007 Safety of sperm washing and ART outcome in 741 HIV 1 serodiscordant couples Human Reproduction 22 3 772 7 doi 10 1093 humrep del422 PMID 17107974 Coutsoudis A Kwaan L Thomson M October 2010 Prevention of vertical transmission of HIV 1 in resource limited settings Expert Review of Anti Infective Therapy 8 10 1163 75 doi 10 1586 eri 10 94 PMID 20954881 S2CID 46624541 U S Approves Drug to Prolong Lives of AIDS Patients New York Times 1987 03 21 Institute of Medicine US Committee for the Oversight of AIDS Activities 1988 Confronting AIDS doi 10 17226 771 ISBN 978 0 309 03879 9 PMID 25032454 Moore RD Chaisson RE April 1996 Natural history of opportunistic disease in an HIV infected urban clinical cohort Annals of Internal Medicine 124 7 633 42 doi 10 7326 0003 4819 124 7 199604010 00003 PMID 8607591 S2CID 20023137 Hammer SM Squires KE Hughes MD Grimes JM Demeter LM Currier JS et al September 1997 A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less AIDS Clinical Trials Group 320 Study Team The New England Journal of Medicine 337 11 725 33 doi 10 1056 NEJM199709113371101 PMID 9287227 S2CID 24043435 a b Sifris D Myhre J 2017 When Did HAART Become ART Change Is About More Than Just Semantics reviewed by a board certified physician a b c Passaes CP Saez Cirion A April 2014 HIV cure research advances and prospects PDF Virology 454 455 340 52 doi 10 1016 j virol 2014 02 021 PMID 24636252 S2CID 205649442 Rosenberg T May 29 2011 The Man Who Had HIV and Now Does Not New York Magazine Retrieved 2014 04 12 Hutter G Nowak D Mossner M Ganepola S Mussig A Allers K et al February 2009 Long term control of HIV by CCR5 Delta32 Delta32 stem cell transplantation The New England Journal of Medicine 360 7 692 8 doi 10 1056 NEJMoa0802905 PMID 19213682 S2CID 14905671 Tebas P Stein D Tang WW Frank I Wang SQ Lee G Spratt SK Surosky RT Giedlin MA Nichol G Holmes MC Gregory PD Ando DG Kalos M Collman RG Binder Scholl G Plesa G Hwang WT Levine BL June CH March 2014 Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV The New England Journal of Medicine 370 10 901 10 doi 10 1056 NEJMoa1300662 PMC 4084652 PMID 24597865 HIV 1 CCR5 gene therapy will fail unless it is combined with a suicide gene Aridaman Pandit amp Rob J de Boer Scientific Reports volume 5 Article number 18088 2016 Senthilingam M 18 July 2016 HIV cure study provides insight into 2008 case CNN Retrieved 21 July 2016 Darmanin M 21 July 2016 No trace of HIV virus after successful stem cell transplantation UtrechtCentral com Retrieved 21 July 2016 2016 Towards an HIV Cure Symposium Programme 16 amp 17 July 2016 PDF Durban International Convention Centre ICC Durban South Africa AIDS Society IAS 21 June 2016 Retrieved 21 July 2016 Levin Jules 19 July 2016 Allogeneic Stem Cell Transplantation in HIV 1 infected individuals the EpiStem Consortium Conference Reports for NATAP IAS Durban HIV cure Symposium July 16 17 2016 National AIDS Treatment Advocacy Project NATAP Retrieved 23 July 2016 Johnson C 5 March 2019 A decade after the first person was cured of HIV a second patient is in long term remission The Washington Post Retrieved 5 March 2019 May A 5 March 2019 HIV patient seemingly cured in second remarkable case London doctors report USA Today Retrieved 5 March 2019 Kang H Minder P Park MA Mesquitta WT Torbett BE Slukvin II December 2015 CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR Cas9 Provides Selective Resistance of Immune Cells to CCR5 tropic HIV 1 Virus Molecular Therapy Nucleic Acids 4 e268 doi 10 1038 mtna 2015 42 PMID 26670276 Charpentier E April 2015 CRISPR Cas9 how research on a bacterial RNA guided mechanism opened new perspectives in biotechnology and biomedicine EMBO Molecular Medicine 7 4 363 365 doi 10 15252 emmm 201504847 PMC 4403038 PMID 25796552 Chomont N El Far M Ancuta P Trautmann L Procopio FA Yassine Diab B et al August 2009 HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation Nature Medicine 15 8 893 900 doi 10 1038 nm 1972 PMC 2859814 PMID 19543283 McNeil Donald 2014 Early Treatment Is Found to Clear H I V in a 2nd Baby The New York Times Persaud D Gay H Ziemniak C Chen YH Piatak M Chun TW et al November 2013 Absence of detectable HIV 1 viremia after treatment cessation in an infant The New England Journal of Medicine 369 19 1828 35 doi 10 1056 NEJMoa1302976 PMC 3954754 PMID 24152233 Archin NM Cheema M Parker D Wiegand A Bosch RJ Coffin JM Eron J Cohen M Margolis DM February 2010 Antiretroviral intensification and valproic acid lack sustained effect on residual HIV 1 viremia or resting CD4 cell infection PLOS ONE 5 2 e9390 Bibcode 2010PLoSO 5 9390A doi 10 1371 journal pone 0009390 PMC 2826423 PMID 20186346 Archin NM Liberty AL Kashuba AD Choudhary SK Kuruc JD Crooks AM et al July 2012 Administration of vorinostat disrupts HIV 1 latency in patients on antiretroviral therapy Nature 487 7408 482 5 Bibcode 2012Natur 487 482A doi 10 1038 nature11286 PMC 3704185 PMID 22837004 Carcelain G Autran B July 2013 Immune interventions in HIV infection Immunological Reviews 254 1 355 71 doi 10 1111 imr 12083 PMID 23772631 S2CID 34104811 Programs TAT Vaccin VIH BIOSANTECH SA www biosantech org Archived from the original on 2016 06 01 Retrieved 2015 10 27 Watkins JD Lancelot S Campbell GR Esquieu D de Mareuil J Opi S et al January 2006 Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV 1 Tat Oyi vaccine Retrovirology 3 8 doi 10 1186 1742 4690 3 8 PMC 1434768 PMID 16441880 Haynes BF Burton DR March 2017 Developing an HIV vaccine Science 355 6330 1129 1130 Bibcode 2017Sci 355 1129H doi 10 1126 science aan0662 PMC 5569908 PMID 28302812 Checkley MA Luttge BG Freed EO July 2011 HIV 1 envelope glycoprotein biosynthesis trafficking and incorporation Journal of Molecular Biology 410 4 582 608 doi 10 1016 j jmb 2011 04 042 PMC 3139147 PMID 21762802 Pardi N Hogan MJ Porter FW Weissman D April 2018 mRNA vaccines a new era in vaccinology Nature Reviews Drug Discovery 17 4 261 279 doi 10 1038 nrd 2017 243 PMC 5906799 PMID 29326426 Richner JM Himansu S Dowd KA Butler SL Salazar V Fox JM et al March 2017 Modified mRNA Vaccines Protect against Zika Virus Infection Cell 168 6 1114 1125 e10 doi 10 1016 j cell 2017 02 017 PMC 5388441 PMID 28222903 The HIV Life Cycle NIH hivinfo nih gov Retrieved 2021 11 30 Fischer W Giorgi EE Chakraborty S Nguyen K Bhattacharya T Theiler J et al July 2021 HIV 1 and SARS CoV 2 Patterns in the evolution of two pandemic pathogens Cell Host amp Microbe 29 7 1093 1110 doi 10 1016 j chom 2021 05 012 PMC 8173590 PMID 34242582 Liao HX Lynch R Zhou T Gao F Alam SM Boyd SD et al April 2013 Co evolution of a broadly neutralizing HIV 1 antibody and founder virus Nature 496 7446 469 476 Bibcode 2013Natur 496 469 doi 10 1038 nature12053 PMC 3637846 PMID 23552890 Pejchal R Doores KJ Walker LM Khayat R Huang PS Wang SK et al November 2011 A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield Science 334 6059 1097 1103 Bibcode 2011Sci 334 1097P doi 10 1126 science 1213256 PMC 3280215 PMID 21998254 Burton DR Hangartner L May 2016 Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design Annual Review of Immunology 34 1 635 659 doi 10 1146 annurev immunol 041015 055515 PMC 6034635 PMID 27168247 McCoy LE October 2018 The expanding array of HIV broadly neutralizing antibodies Retrovirology 15 1 70 doi 10 1186 s12977 018 0453 y PMC 6192334 PMID 30326938 a b c Mu Z Haynes BF Cain DW February 2021 HIV mRNA Vaccines Progress and Future Paths Vaccines 9 2 134 doi 10 3390 vaccines9020134 PMC 7915550 PMID 33562203 a b First in human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research www scripps edu Retrieved 2021 11 30 Jones LD Moody MA Thompson AB March 2020 Innovations in HIV 1 Vaccine Design Clinical Therapeutics 42 3 499 514 doi 10 1016 j clinthera 2020 01 009 PMC 7102617 PMID 32035643 International AIDS Vaccine Initiative 2021 09 29 A Phase 1 Randomized First in human Open label Study to Evaluate the Safety and Immunogenicity of eOD GT8 60mer mRNA Vaccine mRNA 1644 and Core g28v2 60mer mRNA Vaccine mRNA 1644v2 Core in HIV 1 Uninfected Adults in Good General Health ModernaTX Inc The University of Texas at San Antonio George Washington University Fred Hutchinson Cancer Research Center Emory University a href Template Cite journal html title Template Cite journal cite journal a Cite journal requires journal help Kallen A Woloshin S Shu J Juhl E Schwartz L 2007 10 01 Direct to consumer advertisements for HIV antiretroviral medications a progress report Health Affairs 26 5 1392 1398 doi 10 1377 hlthaff 26 5 1392 PMID 17848450 S2CID 12536749 Josefson D May 2001 FDA warning to manufacturers of AIDS drugs BMJ 322 7295 1143 doi 10 1136 bmj 322 7295 1143 PMC 1120280 PMID 11348904 Constitution www who int Archived from the original on March 17 2019 Retrieved 2019 03 07 a b Miners A Phillips A Kreif N Rodger A Speakman A Fisher M et al October 2014 Health related quality of life of people with HIV in the era of combination antiretroviral treatment a cross sectional comparison with the general population The Lancet HIV 1 1 e32 40 doi 10 1016 S2352 3018 14 70018 9 PMID 26423814 a b Gakhar H Kamali A Holodniy M May 2013 Health related quality of life assessment after antiretroviral therapy a review of the literature Drugs 73 7 651 72 doi 10 1007 s40265 013 0040 4 PMC 4448913 PMID 23591907 a b Mak WW Poon CY Pun LY Cheung SF July 2007 Meta analysis of stigma and mental health Social Science amp Medicine 65 2 245 61 doi 10 1016 j socscimed 2007 03 015 PMID 17462800 a b Wolfe D Carrieri MP Shepard D July 2010 Treatment and care for injecting drug users with HIV infection a review of barriers and ways forward Lancet 376 9738 355 66 doi 10 1016 S0140 6736 10 60832 X PMID 20650513 S2CID 13205040 van der Heijden I Abrahams N Sinclair D et al Cochrane Infectious Diseases Group March 2017 Psychosocial group interventions to improve psychological well being in adults living with HIV The Cochrane Database of Systematic Reviews 3 CD010806 doi 10 1002 14651858 CD010806 pub2 PMC 5461871 PMID 28291302 HIV AIDS in NYC PDF Health equity August 11 2022 via Wikipedia External links EditHIVinfo Comprehensive resource for HIV AIDS treatment and clinical trial information from the U S Department of Health and Human Services ASHM Australian Commentary on HHS Guidelines for the use of Antiretroviral Agents in HIV 1 Infected Adults and Adolescents Origins of antiretroviral combination therapy Viral Load research papers including effectiveness of HAART on reducing viral load Current status of gene therapy strategies to treat HIV AIDS Portals Medicine Viruses Retrieved from https en wikipedia org w index php title Management of HIV AIDS amp oldid 1123118830, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.